

A Modern Review of the Non-Invasive Continuous Blood Glucose Measuring Devices and Techniques for Remote Patient Monitoring System

Muhibul Haque Bhuyan

Abstract—Diabetes disease that arises from the higher glucose level due to insulin shortage or insulin opposition in the human body has become a common disease in the world. No medicine can cure it completely. However, by taking medicine, maintaining diets, and having exercises regularly, a diabetes patient can keep his glucose level within the specified limits and in this way, he/she can lead a normal life like a healthy person. But to control glucose levels, a patient needs to monitor them regularly. Various techniques are being used over the last four decades. This modern review article aims to provide a comparative study report on various blood glucose monitoring techniques in a very concise and organized manner. The review mainly emphasizes working principles, cost, technology, sensors, measurement types, measurement accuracy, advantages, and disadvantages, etc. of various techniques and then compares among each other. Besides, the use of algorithms and simulators for the growth of this technology is also presented. Finally, current research trends of this measurement technology have also been discussed.

Keywords—Blood glucose measurement, sensors, measurement devices, invasive and non-invasive techniques.

I. INTRODUCTION

THE foremost energy transporter inside the human body is blood and it comes from its glucose. A healthy person has a glucose level in blood within a normal range of 88-125 mg/dl (4.9-6.9 mmol/l) [1], [2]. Mainly, the insulin inside the human body helps to regulate the glucose level. Insulin is a kind of hormone that discharges from the pancreas to regulate the blood glucose level at a normal range. When we take a meal with carbohydrates then it is transformed into glucose and released into the bloodstream. After that, insulin in the blood aids to carry glucose from the bloodstream into cells where glucose is converted to energy [2]. Thus, if enough insulin doesn't secrete from the pancreas or if enough insulin is secreted but the body cannot make good use of it then the glucose level in the bloodstream rises and creates metabolic chaos inside the human body [3]-[5]. Such type of disorder is called diabetes, which is now worldwide a chronic disease [6].

Based on insulin production, there are two kinds of diabetes disease, such as type 1 and type 2. If the body cannot harvest enough or any insulin at all then it is called type 1 diabetes disease and in this case, the patient depends on insulin to keep the controlled sugar level. On the other hand, if the body can still produce insulin but the body becomes resistant to the

insulin then it is called type 2 diabetes disease and in such case, the patient can keep his body's glucose level controlled by taking any medicine but not the external insulin [7], [8]. If the glucose level falls below the normal lower limit of 88 mg/dl or 4.9 mmol/l then it is called scarcity of glucose in the body or commonly known as hypoglycemia. Alternatively, if the glucose level goes above the normal higher limit of 125 mg/dl or 6.9 mmol/l then it is called surplus of glucose in the body or commonly known as hyperglycemia. Any type of diabetes disease is detrimental in the long run because it invites other diseases like cardiovascular diseases, heart strokes, kidney failures, eye-sightedness or even complete blindness, birth defects, damaged nerve system, sudden coma, memory loss, confusion, and even death.

The number of diabetic patients was projected by the International Diabetes Federation (IDF) as 463 million in 2019 and they are expecting that it may rise to 578 million by 2030 and 700 million by 2045 [9]. Moreover, 4 million people died due to diabetes diseases and their complications, and this costs the world expenditures of US\$727 billion in 2017 [10] and US\$760 billion in 2019 [9].

To have a controlled level of glucose in the bloodstream and to manage diabetes very well, we have to determine blood glucose levels precisely and regularly [11]. At present, there are various types of machines or devices that we may purchase from the retail market to determine the glucose level continuously. In this article, various such machines or devices and their working principles or technologies are discussed in the brief and compared. However, researchers are trying to improve these technologies and hence current research trends are also discussed in this article.

II. BIOLOGICAL ISSUES

Interstitial or intercellular or tissue fluid resides inside the microscopic sections nearby the cell. Glucose molecules can freely move from capillary endothelium to this fluid by a simple process called para-cellular or trans-cellular diffusion process. The amount of the glucose molecules per unit volume in this fluid is dependent on the rate of change of glucose molecules per unit volume of the blood, the metabolic rate of the human body, and the blood flow rate inside the capillaries [12], [13]. There is a substantial time delay or time difference (from 2 min

M. H. Bhuyan is with the Department of Electrical and Electronic Engineering (EEE), Southeast University, Bangladesh. (Corresponding author, phone: 88-01815-657346; e-mail: muhibulhb@seu.edu.bd).

to 45 min) between the highest glucose concentration inside this fluid and that inside the blood. This is given by the sum of the physiological and instrument time delay. The average time delay is 6.7 min [14]. The instrument time delay arises from the researcher's measurement method, and time delay due to physiological parameter fluctuations indicates the time needed to diffuse glucose molecules from the blood into the interstitial spaces of the capillaries [15]. The major challenge of determining the blood glucose level using the non-invasive technique is the determination of this physiological time delay. This problem is principally related to the spectroscopic technologies, which mainly probes intercellular glucose level, produces dissimilarities in the calibration procedures where blood glucose level is used as a reference point [16]. If there is a time delay then the concerned sensors are to be calibrated again to a new blood glucose level at static time gaps. We know that hypo-glycemia and hyper-glycemia problems rely on the glucose molecule concentration. As such, the discrepancy between the glucose levels of the intercellular fluid and blood tells us that the inter-cellular sensors are not suitable for a closed-loop insulin supply scheme. Furthermore, a time delay is faced in the supply and captivation of insulin for the subcutaneous-subcutaneous closed-loop scheme in which inter-cellular fluid is utilized to detect that the glucose molecules and insulin are transported using the sub-cutaneous method [17], [18].

III. TYPES OF BLOOD GLUCOSE MEASUREMENT METHODS

Blood glucose concentration detection techniques are divided into three broad groups, namely invasive, minimally invasive, and non-invasive techniques [19]. There are various sub-classifications of these techniques. This is depicted in a flow diagram of Fig. 1.




Fig. 1 Classification of blood glucose measurement techniques [14]

The invasive method needs to pierce the fingers of a patient to take a drop of blood sample onto a test strip to measure the

blood glucose data. Therefore, it is also known as the finger-pricking method. However, this method is not so popular due to its numerous drawbacks. For example, many patients dislike to see blood coming out from their body, piercing fingers require a fresh needle and a test strip whenever a patient wants to measure his/her glucose level, and it gives some sort of pain to the fingers of the patients, there is a threat of being infected, and in the long run, finger pricking may yield permanent injury to the finger tissue [20].

Conversely, the minimally invasive technique uses subcutaneous sensors to measure the glucose level from the interstitial fluid. However, this method creates some sort of awkwardness to the patients, requires constant calibration, and is seriously susceptible to biofouling [21].

The third category is the in vivo non-invasive blood glucose measurement method by which glucose level is determined from the blood by using a kind of biological sensor having no physical connection with any parts of the human body, and there is no need to take blood samples on a test strip by using any needle to perforate the skin. As such, it is also inexpensive as compared to the invasive method [22]. Researchers are doing investigations on various types of non-invasive methods and algorithms to find the blood glucose level non-invasively. This would allow the diabetic patients to check their glucose levels more regularly and thus they would be able to keep the glucose level in their control.

The non-invasive determination methods are categorized into two major groups, such as (i) the transdermal method and (ii) the optical method.

The transdermal method uses the physical energy of the human body to have interstitial fluid or blood. Using some appropriate technology or algorithm, the glucose levels are then extracted. However, this method suffers from the problems of changes in skin properties and may originate blistering, burning, irritation, pains, and erythema.

Alternatively, the optical method uses photonic signals to get information from the glucose molecule inside the ISF, blood, or inner chambers of the eyes. Then glucose levels are detected based on microcontroller-based algorithms [14].

The transdermal and optical methods are sub-categorized further and are shown in Fig. 1.

IV. WORKING PRINCIPLES OF NON-INVASIVE BLOOD GLUCOSE MEASUREMENT DEVICES

There are various forms of non-invasive blood glucose measurement methods available in the literature. This is shown in Fig. 1. In this section, a summary of the devices that are made using those techniques is given. Here only optical methods are discussed as these are now very popular methods.

These methods use a particular range (optical frequency) of the electromagnetic spectrum. The electromagnetic signal is propagated through the body tissue to interact with the glucose and other parts inside the tissues. Then the transmitted and reflected signal from the tissue is gathered and investigated to find the number of glucose molecules per unit volume of the tested tissues. Then a better selection algorithm is applied to determine the exact amount of right components without any

intervention of other parts in the sample. Then data is calibrated to compute the exact amount of glucose in the patient's body. Several algorithms and calibration methods are being established by several researchers around the world to increase the accuracy and precision levels of the data.

A. Near Infra-Red Spectroscopic Method

The systems that use the near-infra-red (NIR) spectroscopic method comprise a light-emitting source, optical fiber cable, photo-detector, etc. The optical signal, in the NIR region (700-1700 nm) for the Glucose spectra, is sent from the light source to the human body's tissue with a scanning rate of a spectral rate of 1800 spectra/s [23]. When it returns from there, it is captured by a photo-detector via the optical fiber. The collected signal is then converted into an equivalent voltage signal, which is very low in amplitude. So, it is then amplified via an amplifier. The amplified signal is then transformed into a digital signal and finally fed to the digital processor's input, such as the microcontroller [24]. After that, various signal processing techniques and multivariate analytic calibration models are applied to extract glucose levels in the blood according to the variation of the light intensity [23]. Finally, the extracted value is displayed on the screen, such as on an LCD unit with an appropriate unit of glucose level. Usually, the Clarke Error Grid (CEG) technique is utilized to check the clinical accuracy of the measured data [25]. A simple block diagram is depicted in Fig. 2.




Fig. 2 Block diagram of the NIR-spectroscopic based blood glucose measurement (BGM) system

B. Mid and Far Infra-Red Spectroscopic Method

These two methods are very much similar to the near-infra-red spectroscopic method, but the main difference is that the parts of the body from where the measurement, i.e. the light emission and detection would be made and the emission spectra of the optical signal. The mid-infrared (mid-IR) mobile sensor-based Quantum Cascade LASER (QCL) with a sphere was used to find glucose contents transmitting and receiving LASER light to and from the human skin. The block diagram of such a system is presented in Fig. 3. The transmitted light is absorbed by the glucose molecules and then the back-scattered highly divergent light signal from the dermis layer is received by a miniaturized integrating sphere from where the signal is sensed by using a thermoelectrically cooled mercury cadmium telluride (HgCdTe) detector [26]. The spectra were smoothed using a Savitzky-Golay filter [27] and then the Principal Component Analysis (PCA) technique [28] is utilized to analyze and count the glucose content from the absorption co-

efficient of the spectrum using a Fourier Transform Infra-Red (FTIR) transmission spectroscopy [29].




Fig. 3 Block diagram of the mid-infrared mobile sensor and QCL spectroscopy-based blood glucose measurement system

C. Photoacoustic Spectroscopy Method

The photoacoustic spectroscopy-based system comprises a LASER diode, a projection system, a transducer, optical fiber, a microcomputer, and a display unit [30]. In this method, very short period laser pulses (of the order of a few nano-seconds) are sent to the human body to stimulate blood glucose [31]. This generates heat energy into the local cells, expands those to yield the acoustic wave, which is then sensed by the piezoelectric transducer [32]-[34]. The peak-to-peak value of the reflected acoustic wave gives the amount of blood glucose data and also the total incident energy [35]. Finding the glucose level data by using such a method depends mainly on measuring the alterations of acoustic wave parameters that differ according to the glucose contents [36]. However, there are some detection errors in this method due to several limitations. To alleviate such errors partially, the ultrasound frequency band (50-60 kHz) is used to obtain a greater Signal-to-Noise Ratio (SNR). A simple block diagram of this kind of system is given in Fig. 4.




Fig. 4 Block diagram of the photoacoustic spectroscopy-based blood glucose measurement system

D. Raman Spectroscopy Method

This system consists of primarily a LASER source, lenses, prism, spectrometer, and detector. Fig. 5 depicts a schematic diagram of a Raman spectroscopy-based system. LASER beam, placed with a Raman imaging microscope, is transmitted through filter, lenses, and prisms to focus onto the human tissue. Back scattered light from the tissue is passed into a notch filter to eliminate unwanted components from the optical signal which is then sent to the spectrometer to be collected by a

detector [37]. The glucose contents are detected using the Charged Coupled Device (CCD) array detector from the Raman active molecules, which deliver a quantifiable Raman signal. In such a system, the LASER spectrum should be within a range between 700-900 nm [38]-[40]. However, this method also has some limitations that are evaded in its advanced versions like surface-enhanced Raman spectroscopy, stimulated Raman spectroscopy, coherent anti-stokes Raman scattering, and resonance Raman spectroscopy techniques [41]. The Partial Least Square Regression (PLSR) method is employed to calibrate the model to compute the glucose concentration in the blood [42]. A simple block diagram of such a system is depicted in Fig. 4.




Fig. 5 Block diagram of the Raman spectroscopy-based BGM system

E. Optical Coherence Tomography Method

The Optical Coherence Tomography (OCT) process is employed for cross-sectional imaging in biological organs [43], [44]. It works based on the principles of Michelson's interferometer. This method uses a low coherence light source, optical fiber, optical coupler, optical splitter, mirrors, lenses, photodetector, and a display unit as depicted in Fig. 6. Two sections of the human body are used to measure the glucose level, viz. a tissue, and a reference arm. Back scattered light comes from the tissue and the reflected light comes from the reference arm as detected by the photodetector. Then they are mixed in a spectrometer and refractive indices between sample tissue and reference arm are analyzed by measuring the time delay between the reflected light and backscattered light [45]-[49]. The degree of mismatch between the refractive indices based on the OCT procedure indicates the amount of glucose level in the blood as evaluated by the Linear Least-Squares Regression (LLSR) method in the microcomputer [50]. Finally, the results are displayed on the screen.




Fig. 6 Block diagram of the optical coherence tomography technique based BGM system

F. Metabolic Heat Conformation Method

Metabolic Heat Conformation (MHC) means there is a direct connection between body temperature and glucose quantity. The glucose level in the human body is directly dependent upon the hemoglobin level, oxygen supplied to the hemoglobin, blood flow rate, and metabolic heat. Therefore, the glucose level can be determined by measuring these parameters of the body. Such a schematic illustration is shown in Fig. 7.




Fig. 7 Block diagram of the metabolic heat conformation technique based BGM system

In this method, the temperature is sensed from the finger by a thermopile detector inside the sensor. Then the blood flow rate is measured by the temperature difference between the two thermistors that are contacted with the finger. After that, hemoglobin and oxygenated hemoglobin levels are measured based on the diffuse reflectance spectroscopic method. Six LED light sources produce optical signals with six different wavelengths (470, 535, 660, 810, 880, and 950 nm) that are used to get a reflectance spectrum from the photodetectors connected at various surface areas of the finger, and then absorbance values are calculated using known formulas. [51]-[55]. Finally, the glucose concentration is computed based on stepwise regression analysis in the microcomputer and after performing the calibration, data are displayed.

G. Fluorescent Method

This method uses the method of Fluorescence Resonance Energy Transfer (FRET). In such an organization, energy is transported between two fluorophore molecules when their distance is less than the Forster radius (the maximum gap, of the order of 5-6 nm between the particles after which energy transfer doesn't take place) [56], [57]. Fig. 8 shows a block diagram representation of the fluorescent method.




Fig. 8 Block diagram of the fluorescent technique based BGM system

An ultraviolet LASER light with a wavelength of 380 nm incidents on human tissue to create the fluorescence effect

there. When the light is reflected from there it contains two components, one is the reflected light coming from the induced emitted light because of the interactions that occurred between the glucose molecules in presence of water inside the sample and the second one is the exciting light. The photodetector senses these reflected optical signals and produces signals based on their intensity to provide necessary information to compute the number of glucose molecules per unit volume in the sample using the Partial Least Square Regression (PLSR) technique [58]-[60]. Special types of disposable and portable contact lenses have been made using polymer film to find glucose concentration in tears.

H. Occlusion Spectroscopy Method

The method is devised by using the fact that there is a direct relationship between glucose concentration level and the scattering characteristics of the human body. If the amount of glucose molecules per unit volume rises then the refractive index mismatch between the scattering body and their adjacent area reduces. Hence, the scattering coefficient and the optical path are abridged. So, if glucose concentration increases then a fewer number of photons are absorbed, and thus the reflected light intensity increases. To facilitate the measurement process, pressure is given by using a pneumatic cuff to stop blood flow for few seconds, and thus a pulse is induced into the blood to change its level. Simultaneously, a time-varying optical signal is sensed by a photodetector from which the glucose level is estimated using the Deming regression analysis [61]-[63]. A system is shown in the block diagram of Fig. 9.




Fig. 9 Block diagram of the fluorescent technique based BGM system

I. Kromoscopy Method

Kromoscopy method is a multi-channel, real-time correlated method having a series of overlapped band-pass filters in the wide band of frequencies to ascertain the amount of glucose concentration in the blood [64], usually within a range of wavelength in between 800-1300 nm near infra-red (NIR) spectra [65]. A simple block diagrammatic illustration is shown in Fig. 10.

In this method, an optical signal having infra-red (IR) spectra is passed through the human tissue. The transmitted optical signal is then decomposed into four parts using photo-detectors using band-pass filters. Each detector examines the tissue structure and then evaluates glucose concentration from interferences using a complex vector analysis method in the microcomputer [66]-[68].




Fig. 10 Block diagram of a BGM system based on Kromoscopic method

J. Bio-Impedance Method

It has been observed that the bio-impedance shrinks linearly with the growing glucose level [69]. In this method, the input signal from the bio-impedance sensor is applied to the amplifier and signal conditioner circuit, which is interfaced with the microcontroller through its bus. The amplitude and phase angle of the current signal flowing through the load is influenced by its impedance. The current signal is converted to the voltage signal, which is then transformed into a digital signal by using an Analog to Digital Converter (ADC) through sampling and quantization techniques. The bio-impedance is measured in the frequency range of 10-100 kHz using silver electrodes as the electrical contact with the human body.

A special circuit generates the Discrete Fourier Transform (DFT) of the modified impedance signal and separates the real and imaginary quantities from the measured data. After processing the data in the microcontroller based on the bio-impedance variation using the multivariate Partial Least Squares (PLS) regression model, the glucose contents are computed and then finally, displayed on the display with the appropriate unit. This data can be transferred to a database using the Universal Asynchronous Receiver Transmitter (UART) interface of the micro-controller unit. The block diagram of such a system is illustrated in Fig. 11.




Fig. 11 Block diagram of a BGM system based on Bio-impedance method

K. Millimeter-Wave Antenna Method

The millimeter-wave antenna method uses a proximity micro-strip patch antenna with operating frequency in the range of millimeter-wave band of 50-60 GHz [70]. The patch antenna transmits electromagnetic wave energy to the human body and then S_{11} or the return loss parameter (in dB), which is the amount of power reflected from the antenna, is measured to ascertain the glucose contents. The complex part of the dielectric permittivity of blood-glucose solution changes with

glucose contents and frequency of the signal. The higher the glucose contents and frequency of the signal, the lower the relative dielectric permittivity (ϵ_r), and hence lesser the return loss is [71], [72]. The system block diagram of the millimeter-wave antenna-based method is shown in Fig. 12.




Fig. 12 Block diagram of a BGM system based on millimeter-wave patch antenna method

L. Microwave Sensor Based Method

A portable planar microwave sensor-based non-invasive glucose level detecting method is available for fast, accurate, and effective measurement of blood glucose [73]. Hexagonal-shaped Complementary Split Ring Resonators (CSRRs), fabricated on a dielectric material are used as the sensing [74] components, which are attached through a planar microstrip-line to a RADAR board functioning in the microwave frequency range of 2.4-2.5 GHz [75]. The human body resonates with the electromagnetic fields when it is exposed to the CSRR sensing components that can sense extremely subtle discrepancies in the electromagnetic properties of the glucose contents. Data is analyzed using a Vector Network Analyzer (VNA) that can record prominent smidgeons of frequency-shift output responses when the sensor is in contact with the human body [76]. The sensor responses are enumerated by relating the Principal Component Analysis (PCA) based on Machine Learning Algorithm (MLA). The working block diagram is shown in Fig. 13.




Fig. 13 Block diagram of a BGM system based on microwave sensor

M. Radio Frequency Antenna Method

A small-size transplantable Radio Frequency (RF) antenna is used as a biosensor to monitor the glucose level inside the human body. In this system, the antenna is prepared using a fully bio-compatible material, viz. cubic silicon carbide (SiC). SiC is a kind of semiconducting material that possesses the properties of both biocompatibility and sensing. Besides, it is chemically inert, tribologically superior, and hemocompatible. The SiC-based antenna can detect the changes in its nearby

medium through the changes of its parameters, such as input impedance and resonance frequency. The S_{11} or return loss parameter (in dB) is used to determine the glucose contents. Then it is measured and analyzed using Vector Network Analyzer. This property of the RF antenna is utilized to ascertain the plasma glucose of a person with an operating frequency of the order of 10 GHz [77]. Sometimes, a Cu patch antenna is used with the SiC antenna as a reference antenna. Besides, a semi-insulating 4H-SiC substrate layer is given to keep the RF losses at a minimum level during the system operation. The simple block diagram of this scheme is exemplified in Fig. 14.




Fig. 14 Block diagram of a BGM system based on RF antenna sensor

N. Ultrasound Sensor Method

The ultrasound sensor-based method uses the transmission time of ultrasound waves in the low-frequency range of the order of 20 kHz or more through the human body fluid. It has been observed that the glucose concentration rises with the propagation time of the ultrasonic wave. The inter-molecular bonding forces and the body's fluid density determine the amount of compression of the fluid or tissue and hence the acoustic velocity at ultra-sound wave frequency there [64]. As a result, any variations of the glucose concentration in the cellular fluid change the density and adiabatic compressibility as well as the acoustic impedance. The ultrasound wave, produced by a transmitter, is transmitted through the human tissue's extracellular fluid to make changes of the glucose concentration based on the strength of intermolecular bonding forces and the density of the fluid [36]. This ultrasound wave voyages through the tissue with a characteristic velocity and is received from the opposite end of the tissue. The received signal is then adjusted for environmental effect, for example, the impact of ambient temperature on the propagation velocity, otherwise, the precision of the results would be compromised. The method of heat capacity and conductivity measurement non-invasively utilizing the ultrasound or spectroscopy technology respectively to measure the glucose contents based on such a two-parameter approach was applied in a product named Gluco-Track [78] though this was a not successful product commercially, good clinical trial results were found out in the literature [36]. However, another research group of Lee et al. conveyed their results on rat skin in a paper after laboratory trials [78]. The simple block diagram of this type of ultrasound sensor-based system is exposed in Fig. 15.




Fig. 15 Block diagram of a BGM system based on ultrasound sensor

O. Surface Plasmon Resonance Method

When a group of coherent charge-density waves, also known as Surface Plasmon Polaritons (SPPs), are agitated by an electromagnetic field emitted onto a highly conductive and chemically inert thin metallic layer, viz. gold (Au) then the Surface Plasmon Resonance (SPR) phenomenon is observed. This phenomenon was used to devise an SPR sensor for finding the low-valued sugar concentrations [79]-[82]. The SPR yields an exponentially decreasing (evanescent) highly sensitive electric field that causes to alter the refractive index of the neighboring medium and thus the SPR peak to occur. Due to the shift of the resonant frequency, also called the SPR shift, in the reflected curve, the fluctuations of the refractive index (η) in the boundary are measured and this indicates the glucose level variation of the medium under test [79].

As per the block diagram of Fig. 16, the basic structure uses the Kretschmann arrangement with a monochromatic LASER light source to radiate a Transverse Magnetic (TM) polarized or p-polarized light wave through a prism [83]. In non-resonant situations, the ray is totally reflected when it touches the prism-metal boundary, but it doesn't resonate with the free electrons available on the metallic surface, and thus only an evanescent electric field exists. This field is vertical to the metal layer. However, at the resonance angle of incidence, θ_R , the momentum of the incoming light becomes equal to that of the electromagnetic field created by the plasma vacillations of the free electrons. This creates a coupling between the free electrons oscillations and the evanescent field and as a result, the photons are absorbed through the metallic sheet, triggering a severe intensity loss in the received power. Therefore, the resonating angle can characterize the tissue if its refractive index (η) can change based on the absorbed optical power.




Fig. 16 Block diagram of a BGM system based on Surface Plasmon Resonance method

Furthermore, SPR can also be obtained by transmitting a polychromatic light signal to the prism-metal boundary at a constant angle of incidence. When the momentum at a certain arriving wavelength equals that of the SPPs then a minimum of the light ray at that specific wavelength may be present in the returned light ray as well. Thus spectral interrogation mode yields. This resonance wavelength can change heavily the refractive index of human tissue [84].

The block diagram of the Surface Plasmon Resonance (SPR) phenomenon-based system is demonstrated in Fig. 16.

P. Advantages of Non-invasive Measuring Devices

There are many advantages that we may get using non-invasive blood glucose measurement devices instead of their invasive or minimally invasive counterpart. The important advantages are listed as follows based on the literature survey:

- Less expensive, affordable cost
- Painless or pain-free
- No extra needle is required
- Minimum health risk
- Continuous monitoring is possible
- Compact in size
- Simple fabrication process
- High sensitivity
- More accurate and precise data
- Possibility of integrating with the Internet-of-Medical-Things (IoMT)
- Wearable and non-wearable versions
- Intelligent implantable medical devices
- Prospective biologically interfaced neural networks
- Possibility of remote monitoring.

V. CHALLENGES OF NON-INVASIVE BLOOD GLUCOSE MEASUREMENT DEVICES

Despite numerous advantages, lots of challenges are being faced with non-invasive blood glucose measurement devices. These have discoursed in the following few paragraphs:

Several types of electromagnetic biomedical sensors are being used in the mm-wave band. But the main challenge in this band is to detect small changes in the signals from the human tissues. If such small changes can't be detected properly then accurate detection of blood sugar levels is also impossible. Besides, there may be complex interactions among the electromagnetic wave signals due to the diffraction and transmission from the tissue surfaces, and there is a great challenge of addressing this issue while designing sensors at the mm-wave band.

Cable stabilization is another issue to diminish amplitude and phase angle drifts during the blood glucose monitoring and measurement process.

Measured data may be unsatisfactory due to the influence of environmental and physiological dynamics during near-infrared measurements, such as the human body and atmospheric temperature or relative humidity, skin color and textures of the patients, etc.

There are so many measurement techniques and algorithms, data collection, analysis, and validation methods. These also

create huge challenges for the researchers to select the suitable one for their works.

If the non-invasive measurement techniques are indirect then the calibration is needed every time, before using the scheme, against the real-time blood glucose levels from which glucose concentration is ascertained from invasive and non-invasive measurements multiple times at various frequency levels. This is done to minimize the impact of individual quasi-stable factors, such as tissue thickness and structure. This makes the system complex, less user-friendly, and time-consuming as well as creates discomfort and dissatisfaction to the patients. As an example, it was found that the OrSense NBM-200G requires a calibration time of 3 hours per day with four measurement data per hour [85]. As such, the challenges are to minimize the calibration frequency and even to eliminate this procedure. However, though most of the non-invasive BGM devices need to calibrate several times, the OrSense NBM-200G device requires only one calibration every 3 hours per day [86].

To make the non-invasive BGM devices highly efficient and simple for a wide variety of users, the most challenging task is to select such a technology that can estimate glucose levels without fresh calibration and getting interfered with any human factors, such as skin properties [87]. We know that the transmission of light at a particular wavelength depends on the thickness, color, and structure of the human skin, bone, blood, and some other materials through which the optical signal travels [88]. Due to these factors, the impedance spectroscopy-based device named Pendra was found impractical for commercial use after several clinical trials on a good number of patients in European countries [89].

The additional critical challenge faced by the non-invasive BGM devices is their practical applicability at home/office. To use such devices there, these must be very simple and portable considering the human factors. Regrettably, most companies hide this information. For example, the Gluowatch device requires that the electrodes should be in place for a minimum duration of 60 minutes during the measurement, but this creates lots of discomfort to the patients [90]. As another example, the GlucoTrack device requires the patient to wait for several minutes before measuring the glucose levels if the patient takes a shower, or performs any physical activities, or enters the house after passing a long time outside [90].

VI. CURRENT RESEARCH TRENDS OF MEASURING METHODS

There are numerous capacities of blood glucose monitoring devices where researchers can carry out their research works. Some of these current research fields are explained in the following sub-sections:

A. Sensors

A non-invasive blood glucose measurement method uses various physical or chemical processes by which the glucose molecules interact inside the human body while flowing through the blood vessels. To get such information, we need some types of artificial biological sensors based on which the non-invasive blood glucose examination devices are being made commercially and these are now available in the market

[91]. To realize non-invasive blood glucose measuring devices, various types of photonic sensors are used. In the literature, the names of numerous photonic sensors are found. In this sub-section, ongoing research trends with such artificial biological sensors are described.

Glucose sensors [14], [92] are being used to quantify the blood glucose data non-invasively to avoid the patient's discomfort and to help them to control diabetes mellitus. The majority of blood glucose sensors used in glucometers are categorized as amperometric and optical sensors.

In the amperometric glucose sensors, the changes in glucose level are measured as a function of current. Sensors contain electrodes that can estimate the current level produced by an enzymatic reaction typically between glucose, an enzyme, and a mediator, and thus it requires an invasive method of measurement. Therefore, the researchers are trying to develop several types of sensors for the non-invasive way of blood glucose measurements and now, we are in the modern era of glucometers with biosensors having auto-calibration options to provide accurate blood glucose values [93]. Photonic sensors like photodiode, photo-transistor, LED, LASER, etc. are being used. Modeling of the sensor designs and simulation at different spectrums are the current areas of research on the non-invasive way of measurement of the blood glucose level of the biological tissues [94]. The researchers are also working on different types of sensor materials with varying pore sizes and surface textures. The application of responsive polymers in implantable biosensors is being investigated. The ultra-sound sensors are also being used to detect the acoustic signal and hence to determine glucose level [78], [95].

A recent research article reports a highly sensitive, non-invasive sensor to get the glucose data from the interstitial fluid in real-time. The system has a chip-less tag sensor that is placed on the patient's skin and a reader by embedding it in a smartwatch. It has investigated on flexible and wearable assembly of non-invasive type sensors on a flexible ultra-thin dielectric as the sensor substrate using microwave resonator as a sensing technique. This is ideal for wearable sensors and consumes no electrical power with high sensitivity and capacity for distant communication [96].

Another recent research paper presented spectroscopy-based non-invasive blood glucose observing scheme to measure the glucose level. Near-infrared transmission spectroscopy is employed and *in vitro* experimentations were conducted, and so had the *in vivo*. The findings of these experimentations were that there is an association between the sensor output voltage and glucose amount [97].

An improved Split Ring Resonator (SRR)-based microfluidic sensor operated at microwave frequency has been characterized at resonant frequency shift. Then the normalized peak attenuation level was found to design the SRR sensor by using the metamaterial-inspired material, such as polydimethylsiloxane, which is biocompatible as well as economical [84].

An epsilon negative (ENG; i.e., with negative dielectric permittivity, $-\epsilon_r$) unit-cell based resonator was used to design a sensor device having a microwave notched filter at its

transmission frequency to get glucose level data from the human body [98].

The other types of sensors used in non-invasive techniques are pyroelectric detectors, thermistors, microwave antennas, etc. Short pulsed LASER rays are used to create thermal energy inside the body. So, the design of such sensors and enhancing their accuracies and precisions are getting important to the current researchers.

Infrared (IR), Micro-Electro-Mechanical System (MEMS), and ultrasonic MEMS technologies are being used to design sensors for continuous glucose monitoring [99]-[101]. In a paper, a MEMS capacitive pressure-based sensor was found to monitor the glucose level continuously [102].

Biosensors are being also designed using Carbon Nanotubes (CNTs), nano-materials, and gold nano-particles as well. They may be employed in the design of blood glucose sensors due to their reliability, accuracy, and faster response [103], [104].

B. Probe Design

The design of the probe is an important issue. From the literature, it was observed that the glucose values vary on the complex di-electric permittivity (ϵ_r) of an aqueous solution and thus the glucose level can be measured from the value of ϵ_r using an open-ended coaxial probe. The obtained results were validated against a commercial probe [105].

Another article investigated the designed probe at a near-field microwave frequency band to detect the glucose concentration level. The designed probe can radiate the signal from its plane in both of its directions. However, the design can be modified to emit the signal unidirectional to maximize the signal emission of the probe and thus to reduce the energy loss. The probe may have multiple layers for better signal transmission unidirectional capacity and higher sensitivity as compared to that of a bidirectional probe [106].

C. Algorithm for the Analysis

A glucose-sensing device is said to be accurate and precise if its sensitivity is more than 15 mg/dl (0.8 mmol/l). After getting the sensor output, several types of analysis are performed based on several types of algorithms. In the literature, numerous multivariate statistical calibration models are found. These algorithms are valuable to simulate and validate various types of non-invasive glucose sensors. The research works are currently going on these algorithms. Some of these important models are Multiple Linear Regression (MLR), Artificial Neural Network (ANN), Principle Component Regression (PCR), Ridge Regression (RR), Partial Least Square Regression (PLSR), Support Vector Machines (SVM), Optimal Control Algorithm (OCA), etc. They are used to fit the measured data to the glucose values. Besides, Clarke Error Grid (CEG) analysis and correlation co-efficient, 'r' are distinctive measurement methods to assess the accuracy level of the glucose sensor [25], [107]-[109].

The complex permittivity data were taken out from the measured complex reflection coefficient (S_{11}) employing the ANN algorithm. The data were tailored to the Debye relaxation model to estimate the glucose concentration (that is, per unit

volume of glucose molecules) at an anticipated frequency. The proposed model is valid for glucose levels of 0 to 16 g/dl in the frequency range of 0.3-15 GHz [105].

The wearable bio-medical device provides model inputs by taking all the required measurements for a patient's blood glucose-insulin values. To establish the proposed control scheme, several patient-specific parameters should be defined concerning a particular day and sampling time. Then a predictive control technique is used to get glucose level data as the controlled variable from which the optimal control steps from the previous sampling instant of the blood-glucose level and the computed value at the prior day is obtained through the Optimal Control Algorithm (OCA). In addition, the patient's blood is monitored to figure out the safe limits of the blood glucose, which are named as preferred blood glucose set-points, or reference values for each time [94].

The Machine Learning (ML) and Neural Network (NN) based methods as well as association with heart rate variability and electrocardiogram are being explored as part of finding a new way of research, innovation, and development to measure the blood glucose level continuously [110].

Numerous Machine Learning (ML) based regression models are being analyzed to develop an optimized regression method. Thus, Classical Least Squares (CLS), Partial Least Squares (PLS), multiway PLS (mPLS), Multiple Linear Regression (MLR), Support Vector Regression (SVR), Logistic Regression (LR), Principal Component Regression (PCR), Multiple Polynomial Regression (MPR), Multivariable Fractional Polynomial (MFP), Neural Network Fitting (NNF), and many more models are being employed to obtain an optimized model to ascertain the blood glucose concentration level precisely [111]. Feed Forward Back-Propagation Deep Combination of Artificial Neural Network (FFBDANN) was also employed to get better results that are obtained using the Artificial Neural Network (ANN) model [112]. Due to the multiple layers and functions, the model is very simple, realistic, and accurate. The hidden layers and their neuron numbers were verified from 20 to 4 to get an optimum value. This is also verified by employing the Artificial Intelligence (AI) model [which are Radial Basis Function (RBF) network, Support Vector Machines (SVM), Feed Forward Artificial Neural Network (FFANN), Random Forest (RF), k-Nearest Neighbor (kNN), Multilayer Perceptron (MLP), and Naive Bayes (NB)] to determine its effectiveness, and thus to validate the Deep Artificial Neural Network (DANN) model [113]-[115].

The test results are called efficient if the convergence time and errors are low but the accuracy is very high. However, it is possible to adjust the number of layers for different test cases to get better results. For this purpose, several training algorithms are applied to train the networks, such as Levenberg Marquart (trainlm), Scaled Conjugate Gradient (trainscg), Resilience Back-Propagation (trainrp), Deep Combination (trainlm, trainscg and trainrp), etc. For example, trainbr training algorithm is used for better detection though its convergence rate is very slow, while trainlm training algorithm is used as an alternative for better classification. The Mean Square Error (MSE) Levenberg Marquart (trainlm) may be employed to

improve the whole training process [116].

Monte Carlo Simulation (MCS) method was also utilized to simulate the propagation of the light signal in skin tissues for the wavelengths ranges from 1200 nm to 1900 nm because skin tissues are the strong scatterers [117], [118]. The MCS can model and simulate the photon transport mechanism in skin tissue layers. Then the light flux is separated into many photons, and each photon is detected using optical property history of the tissue layers, such as the absorption coefficient (μ_a), scattering coefficient (μ_s), refractive index (η), etc. These optical properties of the tissues depend on the wavelength. The skin tissue has three layers, epidermis, dermis, and deeper subcutaneous layers. The depths of these layers are of the order of a few sub-mm to several mm. The optical sources and light detectors were also simulated [119].

D. Design Software

Various design software is used for sensor, device, and probe design and optimization works. Microwave sensors were designed and optimized using a 3-D electromagnetic simulator (Computer Simulation Technology, CST Microwave Studio software) to obtain the highest sensitivity and concentration resolution to get glucose level data [120]. Besides, an electromagnetic solver tool in CST Microwave Studio was employed to determine the resonance performance of the bare Split-Ring Resonators (SRR), masked SRR, and masked SRR through simulation data. The software is used to plot the electric and magnetic field distribution, to get the resonance frequency, to measure transmission and reflection coefficients, etc. [121].

On the other hand, the thumb and the index finger's tissue models were designed in CST Microwave Studio software in a research article. The model could imitate the tissue curvature and its different layers, such as skin, fat, blood, muscle layers, fluid, etc. of the order of 2-3 mm in thickness. Besides, the dielectric properties (such as relative dielectric constant, loss tangent, etc.) of these different layers could be set at different values at a particular operating frequency of the order of GHz range [122].

Design and simulation of MEMS-based capacitive pressure sensor for the detection of blood glucose level were performed by using the electromagnetics interface of the COMSOL Multiphysics software tool. Model definition, materials, and its parameter selection, operational parameter's value set-up, sensitivity analysis, etc. were carried out using the same software tool [102].

Besides, using the COMSOL Multiphysics software tool, a 3-D sensor design and 3-D body modeling were also carried out in another paper. The cross-section of a 3-D abdominal model was generated using the COMSOL Multiphysics comprising skin, fat, muscle, internal organs, and vertebrae (specifically, lumbar vertebrae) bone. The thicknesses of the different layers varied from 3-35 mm [123].

However, the physics-based sensors may be drawn in 3D at SolidWorks and then imported to COMSOL Multiphysics for further simulation and analysis by setting up values of various variables and operational parameters [124].

In another article, the sensor was modeled and fine-tuned to

keep the reflection coefficient at the resonant frequency very low by using the COMSOL Multiphysics [125]. In this and two more articles, it was found that the mathematical models of the dielectric properties of physiological saline-glucose and blood-glucose solutions were implemented in MATLAB numerically and finally, imported to the COMSOL software for numerical design and evaluation of the microwave glucose sensor [125]-[127].

A very recent article presents a microwave biosensor that was designed and simulated using Keysight's Advanced System Design (ADS) electromagnetic simulator on a Gallium Arsenide (GaAs) substrate. Later, it was implemented using micro-fabrication technology to obtain a highly sensitive and resonator-based glucose sensing device. The design parameters are optimized in ADS to attain a low center frequency to enhance the penetration depth and interaction area. High-Frequency Structure Simulator (HFSS) was used to get the simulated electric field intensity patterns at the resonance frequency [128].

E. Future Blood Glucose Measuring Methods

Non-invasive glucose monitoring forms the future of glucose monitoring systems. In this sub-section, some current possible future blood glucose monitoring methods are mentioned. The new technologies that may be creating great interest among researchers are Raman spectroscopy, RF sensors, SPR sensors, optical coherence tomography, photoacoustic spectroscopy, microwave sensors, and fluorescence [129]-[133]. At present, none of these techniques are employed commercially to manufacture bio-medical devices, like in blood glucose measurement devices. To apply these techniques, they must meet the criteria for being the ideal sensors that may produce accurate blood glucose data.

For non-invasive measurement of glucose measurement, the temperature of the human body could also be employed instead of using external light sources to estimate the glucose level. One such temperature-based blood glucose measurement method is called the Metabolic Heat Conformation (MHC) scheme. This method employs the metabolic oxidation process of glucose inside the human body [134], [135].

VII. COMPARATIVE ANALYSIS OF MEASURING METHODS

To get a comparative picture about various types of blood glucose monitoring technologies and devices, it is required to know the error analysis methodologies, approving body's criteria for approval. In the next sub-sections, these issues are addressed gradually.

A. Error Analysis

To examine the accurateness and effectiveness of any type of Blood Glucose Measurement (BGM) device, there are several techniques, guidelines, practices, and standards. The Mean Average Relative Measurement (MARD) and the Error Grids are such metrics to evaluate the accuracy of any device. The standard ISO-15197 describes the guidelines, requirements, and specifications to certify the effectiveness and suitability of any devices before applying them to the human body. Therefore,

most of the countries in the world use ISO prescriptions through their national regulatory bodies before permitting any BGM device for commercial purposes in the country. However, many countries have their guidelines too, for example, the United States. So, a manufacturer must know the regulatory requirements of a particular country and comply with those to commercialize their BGM devices there. The researchers also should know it before adopting any technologies for a BGM device.

1. Mean Absolute Relative Difference

To test the accuracy and precision of the projected glucose level, different parameters, such as Mean Absolute Deviation (MAD), Mean Absolute Relative Difference (MARD), Root Mean Square Error (RMSE), etc. may be computed.

MARD is the most extensively used parameter to evaluate the accuracy and precision of any BGM device because of its easiness [136]. MARD gives the average of the absolute error between all BGM values and corresponding matched reference values. The computation is performed by taking the average of all the absolute errors. Then it is expressed as a single number in percentage. It provides the closeness of the measured data to the real data. The smaller MARD value tells that the BGM device is more accurate than that with the larger MARD value.

The procedure to compute the MARD value is to use two sets of data to be taken at the same instant during clinical trials of a particular BGM device- one set of data is taken by the said device and the other set of data is taken by a standard laboratory method (e.g., YSI-2700). After that, both data are compared and analyzed [137].

Since the MARD value is computed between paired data sets, it can be obtained from the mean value of the Absolute Relative Differences (ARD), therefore, we may use (1) and (2) to compute the MARD value.

$$ARD_k = \frac{|y_{BGM}(t_k) - y_{ref}(t_k)|}{y_{ref}(t_k)} \times 100\% \quad (1)$$

$$MARD = \frac{1}{N_{ref}} \sum_{k=1}^{N_{ref}} ARD_k \quad (2)$$

where y_{BGM} is the data measured by the BGM device, y_{ref} is the data measured by the standard reference device at k^{th} time, t_k , $k = 1, 2, \dots, N_{ref}$, and t_k is the time when data are measured.

Inappropriately, the MARD value is severely reliant on the characteristics and details of the measurement method being employed. As such, comparing the MARD of different devices may be misleading [138]. Hence, the MARD value can't be acceptable completely to define the accuracy level of a BGM device. However, the MARD value may be accepted with some degree of uncertainty [137].

The value of Root Mean Square Error (RMSE) is another parameter that can be computed using (3) [139]. This formula was found appropriate to measure the accuracy level of blood glucose measurement and evaluation system in [140].

$$RMSE_k = \sqrt{\frac{1}{N_{ref}} \sum_{k=1}^{N_{ref}} |y_{CGM}(t_k) - y_{ref}(t_k)|^2} \quad (3)$$

2. Error Grids

To evaluate the clinical accuracy of the blood glucose measurement (BGM) devices, error grids are being used to evaluate qualitatively the tested device [141]. The 2-D grid is a kind of scatter plot of data obtained from the BGM test device and its reference device. It is divided into several zones from where suitability decision on the device is taken based on the percentage of points situated in different zones.

At present, four error grids techniques are employed to evaluate the BGM device accuracy as per different literature reviews, such as Clarke Error Grid (CEG), Parkes Consensus Error Grids (PCEG) for type 1 and type 2 diabetes, and Surveillance Error Grid (SEG). In each method, the plots are divided into five different zones. In CEG and PCEG methods, these zones are designated by five characters from A to E. In the SEG method, these are identified by five color-coded patterns. Due to some pitfalls of the CEG method, the PEG method for two types of diabetes disease was developed. Due to the new regulatory guidelines enacted by ISO and FDA, the device manufacturers are to face severe penalties if there is any inaccuracy in reading is traced [142], and as such CEG and PEG methods are being phased out as tight glycemic control is essential [143]. So, the SEG method was developed and adopted. As per this method, different colors from green to red indicate no risk zone to extreme risk zone for hypo- or hyperglycemia states of the diabetes patients respectively.

However, the Clarke Error Grid (CEG) method was developed to enumerate the medical accuracy of blood glucose data under test as compared to a referenced data using a standard meter [144]. The use of such a technique was found in Diabetes Care published in 1987 [145]. Finally, the EGA was adopted as one of the "gold standards" to decide on the BGM device's accuracy. The Clarke Error Grid (CEG) is a scatter plot of data obtained from a reference BGM meter and a new BGM meter to be tested. The scatter plot is divided into 5 decision-making zones as follows (Fig. 17):

1. If data points are in Region A then these values are within 20% of the reference sensor's values,
2. If data points are in Region B then these values are outside of 20% of the reference sensor's values but won't lead to inappropriate treatment,
3. If data points are in Region C then these values are going to provide unnecessary treatment,
4. If data points are in Region D then these values indicate a potentially dangerous situation and would fail to detect any types of diabetes disease,
5. If data points are in Region E then these values may confuse hypoglycemia for hyperglycemia and vice versa.

Table I provides a summary of each zone. In general, A, B, and Green zones signify the accuracy of the trialed device. The other zones denote the potentially dangerous conditions and need to take applicable remedial actions.




Fig. 17 The Clarke Error Grid (CEG) [144]

TABLE I

CLARK, PARKES, AND SURVEILLANCE ERROR GRIDS TO DECIDE ON THE CLINICAL ACCURACY ASSESSMENT AND EVALUATION OF BGM DEVICES

Risk Zone (Color)	Clarke Error Grid [144]	Parkes Error Grid Type 1 Diabetes [146]	Parkes Error Grid Type 2 Diabetes [146]	Surveillance Error Grid [142]
	A to E	A to E		Green to Dark-red
A (Green)	Clinically correct decisions	No effect on clinical action		No risk
B (G/Y)	Clinically uncritical decisions	Altered clinical action or little or no effect on clinical outcome		Mild risk
C (Y/R)	Over corrections that could lead to poor outcome	Altered clinical action or little or no effect on clinical outcome		Moderate risk
D (Red)	Dangerous failure to detect and treat	Altered clinical action: potential significant medical risk		High risk
E (Dark red)	Erroneous treatment	Altered clinical action: potential dangerous consequences		Extreme risk

3. ISO 15197 Standard

The International Standards Organization (ISO) defines and develops specifications for procedures, services, and products of high quality, reliable and safe products in a wide range of industries, including next-generation medical devices, and others [147], [148].

ISO 15197:2013 and ISO 15197:2015 are the newest standards, released in 2013 and 2015 respectively, for blood glucose measurement devices [149]-[151]. The new standard has tighter accuracy requirements. However, following the new guidelines provides better confidence to patients, clinic owners, and physicians that the measured glucose data are reliable and adequately accurate every time [152].

According to the new standard, 95% of the blood glucose data should fall within ± 15 mg/dL for glucose concentrations less than 100 mg/dL or $\pm 15\%$ at glucose concentrations of 100 mg/dL concerning the reference method. Moreover, 99% of the readings must be inside zones A and B of the Parkes (Consensus) Error Grid for diabetes type 1 [153].

ISO released a harmonized version, EN ISO 15197:2015 for

the European Union countries in 2015 though it did not bring any modification to necessitates for the performance appraisal of the BGM devices [154], [155].

B. Approving Agencies

There are various bodies to approve bio-medical devices in different countries. Some countries have their bodies approve the BGM devices as per their set guidelines and specifications in their lands or territories. Some regions follow the ISO requirements in their territories, for example, the European Medicines Agency. If any BGM device fulfills the ISO guidelines then that device receives the CE mark [156]. However, there is no specific standard for non-invasive blood glucose monitoring devices. Therefore, the BGM device manufacturers comply with the respective national body's rules, regulations, and practices.

Table II provides the regulatory standards to approve the BGM devices in some countries in different parts of the world. Since ISO standards are being changed from 2003 to 2013 and then again in 2015, therefore, the countries that are following the ISO standards, any version of it is acceptable for the new products but the manufacturers should also check the respective national regulatory body's requirements before releasing their products in a particular territory. It may be mentioned that in the regions that follow the ISO guidelines if any manufacturer can comply with the requirements of version 2003 then most of the regions also accept it [152].

C. Device Comparison

Finally, an overview of the status of various devices, with the device and company names, non-invasive continuous blood glucose measurement technologies being applied, placement sites of the human body, device images, accuracy rates, device statuses, etc. are shown in Table III. Various devices are found in the literature and the market, such as GlucoWatch, Diasensors, Apsire, GlucoWise, Gluco-band, GlucoTrack, Orsense, Eversense, Hello Extense, SugarTrac, etc. though their accuracy (that is, how closely a measured value by the BGM device under clinical trial agrees with the reference value of a given standard device, or in other words, how much the measured values are correct) and precision (that is, how closely individual measured value agrees with each other of the same device under trial, or in other words, how many time the measurement can be made very closely indicating the degree of reproducibility of the measured data) are questionable due to the interventions of environmental and physiological parameters as well as experimental set-up.

D. Recommendations






Since the non-invasive method is yet to get approval for clinical purpose, the key technological obstacles must be removed completely before so that its application and commercialization is possible in several countries. At first, the non-invasive blood glucose measuring technologies must be made reliable, safe, user-friendly, and cost-effective to substitute the existing portable devices, like implantable biosensors, or minimally invasive devices. So, in this paper, some important recommendations are given as follows:

- The performance of continuous BGM devices should be pragmatic and comply with the regulatory requirements,
- More monetary investment should be ensured to perform comprehensive clinical trials of the BGM devices to have concrete evidence on the reliability of these devices for all patient groups of various ages and disease types,
- There should be a standard procedure to measure, store and report the BGM device data of clinical trials,
- The reported data should be consistent and accessible to the regulatory bodies and experts,
- There should be clear guidelines on how to approve the BGM device for commercial purposes and how to place the same in the market,
- Before marketing the BGM device, there should be an awareness build-up program to seek cooperation from a diverse group of people and also the information must be communicated to the stakeholders,
- Several investigations are also essential to find the use of non-invasive BGM devices in particular areas, such as, to determine their suitability and duration of use in ICUs,
- The frequency of measurements should also be stated in the clinical trial report,
- The measurement accuracy and precision rates are also need to be mentioned in the trial data
- Any comments or observations during the measurements should also be included in the clinical trial report,
- Finally, any types of side-effects either short-term or long-term must be identified and mentioned explicitly in the clinical trial report.






TABLE II
GUIDELINES TO APPROVE THE BLOOD GLUCOSE MEASUREMENT (BGM) DEVICES IN FEW COUNTRIES

Agency	Country	Guidelines/Standard	Release Year	Device Type	Glucose Level	Criteria	Reference
Food & Drug Administration (FDA)	USA	UCM 380325	2016	BGMS	≥75 mg/dL <75 md/dL	95% within ±12% 98% within ±15%	[157]
Food & Drug Administration (FDA)	USA	UCM 380327	2016	SMBG	Entire range	98% within ±15 mg/dL 95% within ±15% 99% within ±20%	[158]
European Medicines Agency (EMA)	EU	EN ISO 15197	2015		≥100 mg/dL	95% within ±15%	[159]
Health Canada (HC)	Canada	Medical Devices Regulations	2019				[160]
Agência Nacional de Vigilância Sanitária (ANVISA)	Brazil	RDC 40/2015	2015				[161]
China Food & Drug Administration (CFDA)	China	CDS CCG	2009	CGM	<100 mg/dL	95% within ±15%	[162]
Pharmaceuticals and Medical Devices Agency (PMDA)	Japan	ISO 15197	2013	BGMS SMBG			[163], [164]
Therapeutic Goods Administration (TGA)	Australia	Class 1 IVD	2010		Entire range (Type 1 Diabetes)	99% within Zones A & B of Parkes EG	[165]-[167]

TABLE III
COMPARATIVE STUDY OF VARIOUS NON-INVASIVE CONTINUOUS BLOOD GLUCOSE MEASUREMENT (BGM) DEVICES

Measurement Technology	Device and Company Name	Placement Site	Accuracy Rate	Device Image	Status of the Device	Reference
Ultrasonic, Electromagnetic, and Thermal	GlucO-Track (Integrity Applications)	Ear-lobe	96%		Approved and commercialized in Europe	[168]
Fiber Optic Sensor Technology	FiberSense (EyeSense)	Contact lens, tears	95%		The product is available in the market since 2019	[169]
Electric Signal	NovioSense	Basal tear fluid	95%		Phase II clinical trial	[170], [171]
Micro-current Technology	D-SaLife (Dongwoon Anatech)	Saliva	-		Clinical trials completed and trying to get the approval of FDA and KFDA	[172]
Raman Spectroscopy	C8 MediSensors	Abdomen Skin	83%		Approved for sale in Europe	[173]

Measurement Technology	Device and Company Name	Placement Site	Accuracy Rate	Device Image	Status of the Device	Reference
Thermal Emission Spectroscopy (TES)	Infratec Inc.	Tympanic membrane inside the ear canal	89%		The first clinical study with the TES technology showed promising results	[174], [175]
Optical/LASER Technology	GlucoSense (Glucosense Diagnostics under University of Leeds, UK)	Finger	95%		Performed one clinical trial. Aiming for more after further development	[176]
Optical Coherence Tomography	Glucolight (Glucolight Corporation)	Skin	80-95%		Approved by the American Diabetes Association	[177]
Metabolic Heat Conformation	No formal name was given (Hitachi Ltd.)	Finger-tip	91%		Not yet approved for sale	[178]
Bio-Impedance (Electromagnetic Impedance Spectroscopy (EIS) and Electromagnetic Impedance Tomography (EIT))	Biosensors Inc.	Wrist skin	49%		Available in the market	[179]
Photoacoustic Spectroscopy	Aprise Sensor (Glucon Inc.)	Forearm skin	71%		Under development stage, about to commercialize	[180], [181]
MIR Spectroscopy/Optical Parametric Oscillation	No formal name given (Light Touch Technology under National Institutes for Quantum and Radiological Science and Technology)	Finger	99%		Under development stage, about to commercialize	[182]
Metabolic Heat Conformation	G2 Mobile (Eser Digital)	Finger-tip	87%		Available in the market	[183]
mm-Wave Transmission Spectroscopy ($f = 60$ GHz)	Glucowise (MediWise)	Hand	-		Under development stage	[184], [185]
Fluorescence	Eversense® (Senseonics)	Upper arm	95%-99%	 Sensor Transmitter	Available in the market	[186]-[188]
Near Infrared Spectroscopy	Combo Glucometer (Cnoga Medical)	Finger	98-100%		Available in the market	[189]
Occlusion Spectroscopy	OrSense Ltd. (NBM-100G)	Finger	95.5%		Approved by the American Diabetes Association	[86], [190]

Measurement Technology	Device and Company Name	Placement Site	Accuracy Rate	Device Image	Status of the Device	Reference
Impedance Spectroscopy	Pendragon Medical (Pendra®)	Wrist Skin	52%		Approved by CE, but now out of the market due to poor accuracy, trying to develop a multisensory concept	[89]
Near-Infrared Spectroscopy	Tech4Life Enterprises	Nail	-		Currently undergoing trials in several countries.	[191]
Near-Infrared Spectroscopy	HELO Extense (World Global Network)	Finger	>95%		Available in the market	[192]
Reverse Iontophoresis (Electric Current)	SugarBEAT (Nemaura Medical)	Upper Arm	78%		Waiting for CE approval	[193]
NIR Spectroscopy	Wizmi (Wear2b Ltd)	Arm Wrist	94%		Proof of concept	[194]
Near-Infrared Spectroscopy	SugarTrac (LifeTrac System Inc.)	Earlobe	88%	-	Currently in clinical trials, not yet approved or available to the consumers	[195]

VIII. CONCLUSION

In the present review article, the most important non-invasive blood glucose measurement technologies are explained to manufacture various kinds of BGM devices. Most of these BGM devices have some limitations and problems due to environmental factors (e.g., pressure, temperature, air flow, and humidity) as well as physiological parameters e.g., body temperature, sweating, body fluid, and blood perfusion. This causes the measurement values to be incorrect and as a result, these sensors can't fulfill the criteria of an ideal sensor. However, if multiple sensors are used in a BGM device then these effects may be minimized, but in practice, aggregating more sensors in a particular device makes it more complex and increases the manufacturing cost. As a result, strong research plans are undertaken to improve and invent a reliable continuous blood glucose measuring device. Remarkable signs of progress were observed with wearable and portable sensors. However, there are still some major challenges to the researchers. One such challenge is to distinguish the weak glucose signals from the spectral noise, because there may be some other parts with the blood inside the body, like water molecules, ions, etc. The non-invasive techniques must ensure that the glucose spectrum is not influenced by such parts. So, to achieve the high Signal-to-Noise Ratio (SNR) for the non-invasive methods is of paramount importance.

Different multivariate statistical calibration models, such as ANN, DNN, MLS, MLR, LR, NNF, PCR, PLS, mPLS, SVM, SVR, etc. are utilized to chart the measured signal with the

glucose level data. If the SNR can be enhanced using any digital filter then these algorithms are supposed to work better. Calibrations are performed by transfiguring the raw data (e.g., light intensity, response current, etc.) into the glucose level data and then finally, comparing the glucose data with the reference or true data obtained from any standard device.

Another challenge is to design and implement a sensor that can provide stable and reliable data during clinical trials as well as real-time measurement at different situations with an acceptable accuracy range. As such, the sensors should be robust in design, and for this purpose, multidisciplinary research works involving biologists, pharmacists, chemists, material scientists, electrical and electronic engineers, mechanical engineers, computer engineers, mathematicians, statisticians, and physicists must be carried out rigorously.

The other important issue is to make the non-invasive BGM devices user-friendly. Since this device can offer a convenient way of measuring the glucose data painlessly by the patient himself or herself, such device is supposed to popularity among the users for the self-monitoring of the blood glucose levels continuously. In this regard, some of the BGM devices discussed here have already made substantial advancements in the recent past. However, continuous efforts must constantly be made to develop it further by improving the performances in terms of accuracy, precision, cost minimization, reliability, safety, user-friendliness, side-effect-free, etc. There is also a need to emphasize the environmental impacts and to consider several physiological processes of the human body.

If all such issues can be addressed then the researchers of non-invasive BGM devices would certainly be able to curtail the measurement errors that would yield some of the attractive devices shortly.

REFERENCES

- [1] C. E. F. do Amaral and B. Wolf, "Current development in non-invasive glucose monitoring," *Medical Engineering and Physics*, vol. 30, no. 5, pp. 541-549, 2008.
- [2] R. Beebe and J. Myers, "Paramedic Professional Medical Emergencies," *Maternal Health and Pediatric*, vol. 2, second edition, Cengage Learning, 2010, pp. 324-336.
- [3] E. Wilkins and P. Atanasov, "Glucose monitoring: state of the art and future possibilities," *Medical Engineering and Physics*, vol. 18, no. 4, pp. 273-288, 1996.
- [4] J. Peacock, "Diabetes," first edition, Capstone Press, Incorporated, 1999, pp. 4-6.
- [5] J. M. Wojcicki and P. Ladyzynski, "Toward the improvement of diabetes treatment: recent developments in technical support," *Journal of Artificial Organs*, vol. 6, no. 2, pp. 73-87, 2003.
- [6] E. Öztürk, A. K. K. Arslan, M. B. Yerer, and A. Bishayee, "Resveratrol and diabetes: A critical review of clinical studies," *Biomedical Pharmacother*, vol. 95, pp. 230-234, Nov. 2017.
- [7] R. Hanas, "Type 1 Diabetes in Children, Adolescents and Young Adults: How to Become an Expert on Your Own Diabetes," sixth edition, Class Pub., 2010, pp. 5-7.
- [8] D. B. Sacks, M. Arnold, G. L. Bakris, D. E. Bruns, A. R. Horvath, M. S. Kirkman, A. Lermmark, B. E. Metzger, and D. M. Nathan, "Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus," *Diabetes Care*, vol. 34, no. 6, 2011, pp. e61-e99.
- [9] Diabetes Facts and Figures, IDF Diabetes Atlas Ninth edition 2019, <https://idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html>, accessed on 23 August 2021.
- [10] J. d. R. F. Suvi Karuranga, Yadi Huang, Belma Malanda, IDF Diabetes Atlas, 8th Edition. Brussels, Belgium, 2017, pp. 1-150.
- [11] J. Lucisano, T. Routh, J. Lin, and D. Gough, "Glucose Monitoring in Individuals with Diabetes using a Long-Term Implanted Sensor/Telemetry System and Model," *IEEE Transactions on Biomedical Engineering*, vol. 64, no. 9, pp. 1982-1993, Sept. 2017.
- [12] M. S. Boyne, D. M. Silver, J. Kaplan, and C. D. Saudek, "Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor," *Diabetes*, vol. 52, no. 11, pp. 2790-2794, 2003.
- [13] E. Cengiz and W. V. Tamborlane, "A tale of two compartments: interstitial versus blood glucose monitoring," *Diabetes Technology and Therapeutics*, vol. 11, no. 1, pp. S-11-S-16, 2009.
- [14] N. S. Oliver, C. Toumazou, A. E. G. Cass, and D. G. Johnston, "Glucose sensors: a review of current and emerging technology," *Diabetic Medicine*, vol. 26, no. 3, 2009, PMID: 19317813, pp. 197-210.
- [15] E. Kulcu, J. A. Tamada, G. Reach, R. O. Potts, and M. J. Lescho, "Physiological Differences Between Interstitial Glucose and Blood Glucose Measured in Human Subjects," *Diabetes Care*, vol. 26, no. 8, pp. 2405-2409, 2003.
- [16] J. Shao, M. Lin, Y. Li, X. Li, J. Liu, J. Liang, et al., "In Vivo Blood Glucose Quantification Using Raman Spectroscopy," *PLoS ONE*, vol. 7, p. e48127, 2012.
- [17] E. Renard, J. Place, M. Cantwell, H. Chevassus, and C. C. Palerm, "Closed-Loop Insulin Delivery Using a Subcutaneous Glucose Sensor and Intraperitoneal Insulin Delivery: Feasibility Study Testing a New Model for the Artificial Pancreas," *Diabetes Care*, vol. 33, no. 1, pp. 121-127, 2010.
- [18] D. Elleri, D. B. Dunger, and R. Hovorka, "Closed-loop insulin delivery for treatment of type I diabetes," *BMC Med*, vol. 9, no. 9, p. 120, 2011.
- [19] L. Heinemann and G. Schmelzeisen-Redeker, "Non-invasive continuous glucose monitoring in Type I diabetic patients with optical glucose sensors," *Diabetologia*, vol. 41, no. 7, pp. 848-854, 1998.
- [20] C.-F. So, K.-S. Choi, T. K. Wong, and J. W. Chung, "Recent advances in noninvasive glucose monitoring," *Medical Devices*, Auckland, New Zealand, vol. 5, p. 45, 2012.
- [21] S. K. Vashist, "Non-invasive glucose monitoring technology in diabetes management: a review," *Journal of Analytical Chimica Acta*, vol. 750, no. 0, pp. 16-27, 2012.
- [22] O. S. Khalil, "Spectroscopic and Clinical Aspects of Noninvasive Glucose Measurements," *Journal of Clinical Chemistry*, vol. 45, no. 2, pp. 165-177, 1999.
- [23] Y. Yamakoshi, M. Ogawa, T. Yamakoshi, M. Satoh, M. Nogawa, S. Tanaka, T. Tamura, P. Rolfe, and K. Yamakoshi, "A New Non-invasive Method for Measuring Blood Glucose Using Instantaneous Differential Near Infrared Spectrophotometry," *Proceedings of the 29th IEEE Annual International Conference of Engineering in Medicine and Biology Society*, Lyon, France, August 23-26, 2007, pp. 2964-2967, doi: 10.1109/IEMBS.2007.4352951.
- [24] M. H. Bhuyan, S. D. Monty and M. R. Z. Sarkar, "Design and Implementation of an NIR-Technique Based Non-Invasive Glucometer using Microcontroller," *Journal of Bangladesh Electronics Society*, ISSN: 1816-1510, vol. 19, no 1-2, June-December 2019, pp. 75-84.
- [25] M. Ogawa, Y. Yamakoshi, M. Satoh, M. Nogawa, T. Yamakoshi, S. Tanaka, P. Rolfe, T. Tamura, and K. Yamakoshi "Support vector machines as multivariate calibration model for prediction of blood glucose concentration using a new non-invasive optical method named Pulse Glucometry," *Proceedings of the 29th IEEE Annual International Conference of Engineering in Medicine and Biology Society*, Lyon, France, August 23-26, 2007, pp. 4561-4563.
- [26] R. Müller, M. Haertelt, J. Niemasz, K. Schwarz, V. Daumer, Y. V. Flores, R. Ostendorf, and R. Rehm, Thermoelectrically-Cooled InAs/GaSb Type-II Superlattice Detectors as an Alternative to HgCdTe in a Real-Time Mid-Infrared Backscattering Spectroscopy System, *Journal of Micromachines*, vol. 11, 2020, article no. 1124, 14, pages; doi: 10.3390/mi11121124.
- [27] A. Zhao, X. Tang, Z. Zhang and J. Liu, "The parameters optimization selection of Savitzky-Golay filter and its application in smoothing pretreatment for FTIR spectra," *Proceedings of the 9th IEEE Conference on Industrial Electronics and Applications*, 2014, pp. 516-521, doi: 10.1109/ICIEA.2014.6931218.
- [28] K. Polat and S. Güneş, "An expert system approach based on principal component analysis and adaptive neuro-fuzzy inference system to diagnosis of diabetes disease," *Journal of Digital Signal Processing*, ISSN 1051-2004, vol. 17, issue 4, 2007, pp. 702-710, <https://doi.org/10.1016/j.dsp.2006.09.005>.
- [29] D. Kim, I. K. Ilev and J. U. Kang, "Using Mid-Infrared Glucose Absorption Peak Changes for High-Precision Glucose Detection," *LEOS IEEE LASERS and Electro-Optics Society Annual Meeting Conference Proceedings*, 2007, pp. 226-227, doi: 10.1109/LEOS.2007.4382359.
- [30] J. L. Smith, "The Pursuit of Noninvasive Glucose: "Hunting the Deceitful Turkey,"", second edition, 2006, p. 44.
- [31] Z. Zhao and R. A. Myllyla, "Photoacoustic blood glucose and skin measurement based on optical scattering effect," in *Proceeding of SPIE, Optical Technologies in Biophysics and Medicine III*, vol. 4707, Saratov, Russia, July 16, 2002, pp. 153-157.
- [32] O. C. Kulkarni, P. Mandal, S. S. Das, and S. Banerjee, "A Feasibility Study on Noninvasive Blood Glucose Measurement Using Photoacoustic Method," *Proceedings of the IEEE 4th International Conference on Bioinformatics and Biomedical Engineering*, Chegdu, June 18-20, 2010, pp. 1-4.
- [33] Z. Ren, G. Liu, and Z. Huang, "Noninvasive detection of glucose level based on tunable pulsed laser induced photoacoustic technique," *Proceedings of the SPIE International Symposium on Optoelectronic Technology and Application*, vol. 9297, Dec. 3, 2014, pp. 929707-09.
- [34] C. E. F. do Amaral, "Multi-parameter Methods for Non-invasive Measurement of Blood Glucose," PhD Thesis, Electrical Engineering and Information Technology Department, Technical University of Munich, Germany, 2008.
- [35] H. A. MacKenzie, H. S. Ashton, S. Spiers, Y. Shen, S. S. Freeborn, J. Hannigan, J. Lindberg, and P. Rae, "Advances in photoacoustic noninvasive glucose testing," *Journal of Clinical Chemistry*, vol. 45, no. 9, pp. 1587-1595, 1999.
- [36] M. S. Chou, "Method and apparatus for noninvasive measurement of blood glucose by photoacoustics," *United States Patent 6,049,728*, April 11, 2000.
- [37] A. J. Berger, T.-W. Koo, I. Itzkan, G. Horowitz, and M. S. Feld, "Multicomponent Blood Analysis by Near-Infrared Raman Spectroscopy," *Applied Optics*, vol. 38, no. 13, pp. 2916-2926, 1999.

- [38] M. Hunter, A. Enejder, T. Seccina, M. Feld, and W. C. Shih, "Raman spectroscopy for non-invasive glucose measurements," United States Patent US 8,355,767 B2, January 15, 2013.
- [39] A. Ergin, M. Vilaboy, A. Tchouassi, R. Greene, and G. Thomas, "Detection and analysis of glucose at metabolic concentration using Raman spectroscopy," Proceeding of the 29th IEEE Bioengineering Conference, March 22-23, 2003, pp. 337-338.
- [40] A. Ergin and G. Thomas, "Noninvasive detection of glucose in porcine eyes," Proceedings of the 31st IEEE Bioengineering Conference, Northeast, April 2-3, 2005, pp. 246-247.
- [41] J. L. Lambert and M. S. Borchert, "Non-invasive glucose monitor," United States Patent US 6,424,850 B1, Jul 23, 2002.
- [42] E. B. Hanlon, R. Manoharan, T.-W. Koo, K. E. Shafer, J. T. Motz, M. Fitzmaurice, J. R. Kramer, I. Itzkan, R. R. Dasari, and M. S. Feld, "Prospects for in vivo Raman spectroscopy," *Physics in Medicine and Biology*, vol. 45, no. 2, p. R1, 2000.
- [43] J. Popp, V. V. Tuchin, A. Chiou, and S. H. Heinemann, "Handbook of Biophotonics," second edition, Wiley, 2011, p. 2.
- [44] D. Huang, E. A. Swanson, C. P. Lin, J. S. Schuman, W. G. Stinson, W. Chang, M. R. Hee, T. Flotte, K. Gregory, C. A. Puliafito, and J. G. Fujimoto, "Optical coherence tomography," *Science*, vol. 254, no. 5035, pp. 1178-81, 1991.
- [45] J. G. Fujimoto, C. Pitris, S. A. Boppart, and M. E. Brezinski, "Optical coherence tomography: an emerging technology for biomedical imaging and optical biopsy," *Neoplasia*, New York, NY, USA, vol. 2, no. 1-2, p. 9, 2000.
- [46] R. He, H. Wei, H. Gu, Z. Zhu, Y. Zhang, X. Guo, T. Cai, "Effects of optical clearing agents on noninvasive blood glucose monitoring with optical coherence tomography: a pilot study," *SPIE Journal of Biomedical Optics*, vol. 17, no. 10, p. 101513, October 2012.
- [47] K. V. Larin, M. Motamedi, T. V. Ashitkov, and R. O. Esenaliev, "Specificity of noninvasive blood glucose sensing using optical coherence tomography technique: a pilot study," *Physics in Medicine and Biology*, vol. 48, no. 10, p. 1371, 2003.
- [48] M. J. Schurman and W. J. Shakespeare, "Method and apparatus for monitoring glucose levels in a biological tissue," United States Patent US 7,254,429 B2, August 7, 2007.
- [49] A. M. Zysk, F. T. Nguyen, A. L. Oldenburg, D. L. Marks, and S. A. Boppart, "Optical coherence tomography: a review of clinical development from bench to bedside," *SPIE Journal of Biomedical Optics*, vol. 12, no. 5, p. 051403, 2007.
- [50] S. Vaddiraju, D. J. Burgess, I. Tomazos, F. C. Jain, and F. Papadimitrakopoulos, "Technologies for continuous glucose monitoring: current problems and future promises," *Journal of Diabetes Science and Technology*, vol. 4, no. 6, p. 1540, 2010.
- [51] X. Zhang, C. M. Ting, and J. H. Yeo, "Finger temperature controller for non-invasive blood glucose measurement," in Proceeding of SPIE, Optics in Health Care and Biomedical Optics IV, vol 7845, Beijing, China, Oct 18, 2010, pp. 78452X-78452X-6.
- [52] O. K. Cho, Y. O. Kim, H. Mitsuaki, and K. Kuwa, "Noninvasive measurement of glucose by metabolic heat conformation method," *Clinical chemistry*, vol. 50(10), pp. 1894-1898, 2004.
- [53] F. Tang, X. Wang, D. Wang, and J. Li, "Non-Invasive Glucose Measurement by Use of Metabolic Heat Conformation Method," *Sensors*, vol. 8(5), pp. 3335-3344, 2008.
- [54] J. B. Ko, O. K. Cho, Y. O. Kim, and K. Yasuda, "Body metabolism provides a foundation for noninvasive blood glucose monitoring," *Diabetes care*, vol. 27(5), pp. 1211-1212, 2004.
- [55] Z.-C. Chen, X.-l. Jin, J.-m. Zhu, D.-y. Wang, and T.-t. Zhang, "Non-invasive glucose measuring apparatus based on conservation of energy method," *Journal of Central South University of Technology*, vol. 16(6), pp. 982-986, 2009.
- [56] S. Mansouri and J. S. Schultz, "A miniature optical glucose sensor based on affinity binding," *Nature biotechnology*, vol. 2, no. 10, pp. 885-890, 1984.
- [57] G. Eigner, P. I. Sas, and L. Kovács, "Continuous glucose monitoring systems in the service of artificial pancreas," 9th IEEE International Symposium on Applied Computational Intelligence and Informatics (SACI), Romania, May 15-17, 2014, pp. 117-122.
- [58] A. Tura, A. Maran, and G. Pacini, "Non-invasive glucose monitoring: assessment of technologies and devices according to quantitative criteria," *Diabetes Research on Clinical Practice*, vol. 77, no. 1, pp. 16-40, 2007.
- [59] H. V. Hsieh, D. B. Sherman, S. A. Andaluz, T. J. Amiss, and J. B. Pitner, "Fluorescence resonance energy transfer glucose sensor from site-specific dual-labeling of glucose/galactose binding protein using ligand protection," *Journal of Diabetes Science and Technology*, vol. 6, pp. 1286-1295, 2011.
- [60] W. S. Grundfest and M. Stavridi, "Glucose fluorescence monitor and method," United States Patent US5341805 A, August 30, 1994.
- [61] A.-K. M. O. Ola, S. Abdalsalam, R. M. Abd-Alhadi, S. D. Alshmaa, "Design of Simple Noninvasive Glucose Measuring Device," Proceedings of the IEEE Conference on Computing, Electrical and Electronics Engineering, Khartoum, Sudan, August 26-28, 2013, pp. 216-219.
- [62] A. Shinde and R. Prasad, "Non-Invasive Blood Glucose Measurement using NIR technique based on occlusion spectroscopy," *International Journal of Engineering Science and Technology (IJEST)*, vol. 3, pp. 8325-8333, 2011.
- [63] I. Fine, "Non-invasive method and system of optical measurements for determining the concentration of a substance in blood," United States Patent US 6,400,972 B1, June 4, 2002.
- [64] G. Talukdar, "Non-Invasive Measurement of Glucose Content in Human Body: A Comparative Study," Proceeding of 2nd International Conference on Biomedical Engineering for Assistive Technologies, May 29, 2012, pp. 1-6.
- [65] D. Xiang, "Advances in Near-infrared Glucose Monitoring Using Pure Component Selectivity Analysis for Model Characterization and a Novel Digital Micromirror Array Spectrometer," PhD Thesis, The University of Iowa, USA, 2006.
- [66] A. K. Amerov, Y. Sun, M. A. Arnold, and G. W. Small, "Kromoscopic analysis in two- and three-component aqueous solutions of blood constituents," Proceeding of SPIE Conference on Optical Diagnostics and Sensing of Biological Fluids and Glucose and Cholesterol Monitoring, vol. 4263, June 13, 2001, pp. 1-10.
- [67] L. A. Sodickson and M. J. Block, "Kromoscopic analysis: a possible alternative to spectroscopic analysis for noninvasive measurement of analytes in vivo," *Clinical Chemistry*, vol. 40, no. 19, pp. 1838-44, 1994.
- [68] M. J. Block, H. E. Guthermann, and L. Sodickson, "Rapid non-invasive optical analysis using broad bandpass spectral processing," United States Patent US6028311 A, February 22, 2000.
- [69] J. Li, T. Igbe, Y. Liu, Z. Nie, W. Qin, L. Wang, and Y. Hao, "An Approach for Noninvasive Blood Glucose Monitoring Based on Bio-impedance Difference Considering Blood Volume Pulsation," IEEE Access, e-ISSN: 2169-3536, vol. 6, pp. 51119-51129, 22 August 2018, doi: 10.1109/ACCESS.2018.2866601.
- [70] S. Saha, H. C.-Garcia, I. Sotiriou, O. Lipscombe, I. Gouzouasis, M. Koutsoupidou, G. Palikaras, R. Mackenzie, T. Reeve, P. Kosmas, and E. Kallos, "A Glucose Sensing System Based on Transmission Measurements at Millimetre Waves using Micro strip Patch Antennas," *Scientific Reports*, vol. 7, no. 1, doi: 10.1038/s41598-017-06926-1.
- [71] V. Trugul, and I. Kale, "Characterization of the complex permittivity of glucose/water solutions for noninvasive RF/Microwave blood glucose sensing," Proceedings of IEEE International Instrumentation and Measurement Technology Conference (I2MTC), May 2016, doi: 10.1109/I2MTC.2016.7520546.
- [72] M. M. Nazarov, O. P. Cherkasova, and A. P. Shkurinov, "Study of dielectric function of aqueous solutions of glucose and albumin by THz time-domain spectroscopy," *Journal of Quantum Electronics*, vol. 46, pp. 488-495, 2016.
- [73] M. Baghelani, Z. Abbasi, M. Daneshmand, and P. E. Light, "Non-invasive continuous-time glucose monitoring system using a chipless printable sensor based on split ring microwave resonators," *Scientific Reports*, vol. 10, Article no. 12980, 2020, doi: 10.1038/s41598-020-69547-1.
- [74] C. Lee and C. Yang, "Complementary Split-Ring Resonators for Measuring Dielectric Constants and Loss Tangents," *IEEE Microwave and Wireless Components Letters*, vol. 24, no. 8, pp. 563-565, August 2014.
- [75] A. E. Omer, G. Shaker, S. S.-Naeini, G. Alquié, F. Deshours, and H. Kokabi, "Triple-Poles Complementary Split Ring Resonator for Sensing Diabetics Glucose Levels at cm-Band," August 2019.
- [76] A. E. Omer, G. Shaker, S. S.-Naeini, H. Kokabi, G. Alquié, F. Deshours, and R. M. Shubair, "Low-cost portable microwave sensor for non-invasive monitoring of blood glucose level: novel design utilizing a four-cell CSRR hexagonal configuration," *Scientific Reports*, vol. 10, Article number: 15200, 2020.
- [77] S. Afroz, S. W. Thomas, G. Mumcu, C. W. Locke, S. E. Sadow, "A Biocompatible SiC RF Antenna for In-Vivo Sensing Applications," Proceedings of the IEEE Symposium of Materials Research Society, vol. 1433, 2012, doi: 10.1557/opl.2012.1150.

- [78] S. Lee, V. Nayak, J. Dodds, M. Pishko, N. B. Smith, "Glucose measurements with sensors and ultrasound," *Journal of Ultrasound Medicine Biology*, vol. 31, no. 7, pp. 971-977, 2005.
- [79] A. R. Sadrolhosseini, P. M. Nia, M. Naseri, A. Mohammadi, Y. W. Fen, S. Shafie, and H. M. Kamari, "Surface Plasmon Resonance Sensor Based on Polypyrrole-Chitosan-BaFe₂O₄ Nanocomposite Layer to Detect the Sugar," *Applied Sciences*, vol. 10, 2020, Article no. 2855; doi: <https://doi.org/10.3390/app10082855>.
- [80] A. R. Sadrolhosseini, S. A. Rashid, N. Jamaluddin, A. S. M. Noor, and A. M. Isloor, "Surface plasmon resonance sensor using polypyrrole-chitosan/graphene quantum dots layer for detection of sugar," *Materials Research Express*, vol. 6, article no. 075028, 2019.
- [81] C. K. Huang, H. C. Chih, and C. D. Chin, "Interferometric optical sensor for measuring glucose concentration," *Applied Optics*, vol. 42, 2003, pp. 5774-5776.
- [82] A. A. Kolomenskii, P. D. Gershon, and H. A. Schuessler, "Sensitivity and detection limit of concentration and adsorption measurements by laser-induced surface plasmon resonance," *Applied Optics*, vol. 36, 1997, pp. 6539-6547.
- [83] I. Abdulhalim, M. Zourob, and A. Lakhtakia, "Surface plasmon resonance for biosensing: a mini-review," *Electromagnetics Journal*, vol. 28, 2008, pp. 214-242.
- [84] A. M. Shrivastav, U. Cvelbar, and I. A. Abdulhalim, "Comprehensive review on plasmonic-based biosensors used in viral diagnostics," *Communication Biology*, vol. 4, article no. 70, January 2021. <https://doi.org/10.1038/s42003-020-01615-8>.
- [85] K. Rebrin, G. M. Steil, W. P. Van Antwerp, and J. J. Mastrototaro, "Subcutaneous glucose predicts plasma glucose independent of insulin: implications for continuous monitoring," *American Journal of Physiological-Endocrinol Metab*, vol. 277, no. 3 Pt 1, 1999, E561-E571.
- [86] O. Amir, D. Weinstein, S. Zilberman, M. Less, D. Perl-Treves, H. Primack, A. Weinstein, E. Gabis, B. Fikhte, and A. Karasik, "Continuous noninvasive glucose monitoring technology based on "occlusion spectroscopy"," *Journal of Diabetes Science and Technology*, vol. 1, no. 4, July 2007, pp. 463-469, PMID: 19885108; PMCID: PMC2769638, doi: 10.1177/193229680700100403.
- [87] N. A. B. A. Salam, W. H. bin M. Saad, Z. B. Manap, and F. Salehuddin, "The Evolution of Non-invasive Blood Glucose Monitoring System for Personal Application," *Journal of Telecommunication, Electronics and Computational Engineering (JTEC)*, vol. 8, no. 1, 2016, pp. 59-65.
- [88] K-U. Jagemann, C. Fischbacher, K. Danzer, U. A. Mueller, and B. Mertes, "Application of near-infrared spectroscopy for non-invasive determination of blood/tissue glucose using neural networks," *Z Für Physical Chemistry*, vol. 191, 1995, pp. 179-190.
- [89] I. M. E. Wentholt, J. B. L. Hoekstra, A. Zwart, and J. H. DeVries, "Pendra goes Dutch: lessons for the CE mark in Europe," *Diabetologia*, vol. 48, no. 6, pp. 1055-1058.
- [90] C. F. So, K. S. Choi, T. K. S. Wong, and J. Chung, "Recent advances in noninvasive glucose monitoring," *Medical Devices*, Auckland, vol. 5, 2012, pp. 45-52.
- [91] L. Tang, S. J. Chang, C. J. Chen, and J. T. Liu, "Non-Invasive Blood Glucose Monitoring Technology: A Review," *Sensors Journal*, (Basel, Switzerland), vol. 20, no. 23, article no. 6925, 2020, doi: <https://doi.org/10.3390/s20236925>.
- [92] D. Bruen, C. Delaney, L. Florea, and D. Diamond, "Glucose Sensing for Diabetes Monitoring: Recent Developments," *Sensors Journal* (Basel, Switzerland), vo. 17, no. 8, article no. 1866, 2017. <https://doi.org/10.3390/s17081866>.
- [93] K. S. Khadilkar, T. Bandgar, V. Shivane, A. Lila, and N. Shah, "Current concepts in blood glucose monitoring," *Indian Journal of Endocrinology and Metabolism*, vol. 17, 2013. S643-S649, doi: 10.4103/2230-8210.123556.
- [94] A. Gorst, K. Zavyalova, V. Yakubov, A. Mironchev and A. Zapasnoy, "Theoretical Simulation of the Near-Field Probe for Non-Invasive Measurements on Planar Layers with Biological Characteristics," *Bioengineering Journal*, vol. 7, article no. 0149, 2020, pp. 1-16, doi: 10.3390/bioengineering7040149.
- [95] E.-Y. Park, J. Baik, H. Kim, S.-M. Park, and C. Kim, "Ultrasound-modulated optical glucose sensing using a 1645 nm laser," *Scientific Reports*, vol. 10, article no. 13361, 2020.
- [96] M. Baghelani, Z. Abbasi, M. Daneshmand, and P. E. Light, "Non-invasive continuous-time glucose monitoring system using a chipless printable sensor based on split ring microwave resonators," *Scientific Reports*, vol. 10, Article # 12980, 2020, <https://doi.org/10.1038/s41598-020-69547-1>.
- [97] S. Haxha and J. Jhoja, "Optical Based Noninvasive Glucose Monitoring Sensor Prototype," *IEEE Photonics Journal*, vol. 8, no. 6, pp. 1-11, December 2016, article # 6805911, doi: 10.1109/JPHOT.2016.2616491.
- [98] R. Kumari, P. N. Patel, and R. Yadav, "An ENG resonator-based microwave sensor for the characterization of aqueous glucose," *Journal of Physics D: Applied Physics*, vol. 51, no. 7, January 2018, p. 075601, doi: 10.1088/1361-6463/aaa5c5.
- [99] Y. Zhao, S. Li, A. Davidson, B. Yang, Q. Wang, and Q. Lin, "A MEMS viscometric sensor for continuous glucose monitoring," *Journal of Micromechanics and Microengineering*, IOP Publishing, vol. 17, 2007, pp. 2528-2537, doi: 10.1088/0960-1317/17/12/020.
- [100] X. Huang, S. Li, D. Li, Q. Wang, and Q. Lin, "A MEMS Dielectric Affinity Glucose Biosensor," *Journal of Microelectromechanical Systems*, vol. 23, no. 1, pp. 14-20, doi: 10.1109/JMEMS.2013.2262603.
- [101] T. B. Chiddarwar and W. Patil, "Design of Sensitive MEMS Differential Dielectric Sensor for Glucose Measurement," *International Journal of Computing and Technology (IJCT)*, vol. 1, issue 3, ISSN: 2348-6090, April 2014.
- [102] N. Samyuktha, P. Maneesha, B. R. Sreelakshmi, P. K. Pattnaik, and K. Narayan, "Application of MEMS based capacitive sensor for continuous monitoring of glucose," *IEEE Region 10 Conference (TENCON 2015)*, Macao, China, pp. 1-4, doi: 10.1109/TENCON.2015.7372771.
- [103] H. Gergeroglu, S. Yildirim, and M. F. Ebeoglugil, "Nano-carbons in biosensor applications: an overview of carbon nanotubes (CNTs) and fullerenes (C₆₀)," *SN Applied Sciences*, vol. 2, article no. 603, March 2020. <https://doi.org/10.1007/s42452-020-2404-1>.
- [104] M. Sireesha, V. J. Babu, A. S. K. Kiranm, and S. Ramakrishna, "A review on carbon nanotubes in biosensor devices and their applications in medicine," *Journal of Nanocomposites*, Taylor and Francis, vol. 4, no. 2, pp. 36-57, doi: 10.1080/20550324.2018.1478765.
- [105] V. Turgul and I. Kale, "Permittivity extraction of glucose solutions through artificial neural networks and non-invasive microwave glucose sensing," *Sensors and Actuators A: Physical*, vol. 277, July 2018, pp. 65-72, <https://doi.org/10.1016/j.sna.2018.03.041>.
- [106] A. Gorst, K. Zavyalova, A. Mironchev, A. Zapasnoy, and A. Klokov, "Simulation and Experimental Study of the Near Field Probe in the Form of a Folded Dipole for Measuring Glucose Concentration," *Applied Sciences*, vol. 11, article # 5415, 2021, pages 19, doi: <https://doi.org/10.3390/app11125415>.
- [107] M. A. Arnold, "Non-invasive glucose monitoring," *Current Opinion in Biotechnology*, vol. 7, no. 1, pp. 46-49, 1996.
- [108] J. Nyström, B. Lindholm-Sethon, L. Stenberg, S. Ollmar, J. W. Eriksson, and P. Geladi, "Combined near-infrared spectroscopy and multi-frequency bio-impedance investigation of skin alterations in diabetes patients based on multivariate analyses," *Journal of Medical and Biological Engineering and Computing*, vol. 41, no. 3, pp. 324-329, 2003, <https://doi.org/10.1007/BF02348438>.
- [109] D. J. Cox, W. L. Clarke, L. Gonder-Frederick, S. Pohl, C. Hoover, A. Snyder, L. Zimbleman, W. R. Carter, S. Bobbitt, and J. Pennebaker, "Accuracy of perceiving blood glucose in IDDM," *Diabetes Care*, vol. 8, no. 6, pp. 529-536, 1985, PMID: 4075939 doi: 10.2337/diacare.8.6.529.
- [110] M. Gusev, L. Poposka, G. Spasevski, M. Kostoska, B. Koteska, M. Simjanoska, N. Ackovska, A. Stojmenski, J. Tasic, and J. Trontelj, "Noninvasive Glucose Measurement Using Machine Learning and Neural Network Methods and Correlation with Heart Rate Variability," *Journal of Sensors*, Hindawi Publishing, vol. 2020, Article ID: 9628281, 13 pages, <https://doi.org/10.1155/2020/9628281>.
- [111] Z. Zhang, "A mathematical model for predicting glucose levels in critically-ill patients: the PIGNOLI model," *PeerJ*, 3:e1005, pages 11, June 9, 2015, doi: 10.7717/peerj.1005.
- [112] V. Nademi, "Improved Blood Glucose-Insulin Monitoring with Dual-Layer Predictive Control Design," *International Journal of Biomedical and Biological Engineering*, vol. 12, no. 9, 2018, pp. 398-402.
- [113] M. Catalogna, E. Cohen, S. Fishman, Z. Halpern, U. Nevo, and E. Ben-Jacob, "Artificial Neural Networks Based Controller for Glucose Monitoring during Clamp Test," *PLOS ONE* vol. 7, no. 8, August 2012, article no. e44587, doi: <https://doi.org/10.1371/journal.pone.0044587>.
- [114] P. Jain, A. M. Joshi, and S. P. Mohanty, "iGLU: An Intelligent Device for Accurate Noninvasive Blood Glucose-Level Monitoring in Smart Healthcare," *IEEE Consumer Electronics Magazine*, vol. 9, no. 1, pp. 35-42, 1 January 2020, doi: 10.1109/MCE.2019.2940855.
- [115] A. M. Joshi, P. Jain, S. P. Mohanty, and N. Agrawal, "iGLU 2.0: A New Wearable for Accurate Non-Invasive Continuous Serum Glucose Measurement in IoMT Framework," *IEEE Transactions on Consumer*

- Electronics, vol. 66, no. 4, pp. 327-335, Nov. 2020, doi: 10.1109/TCE.2020.3011966.
- [116] M. Islam, M. S. Ali, N. J. Shoumy, S. Khatun, M. S. A. Karim, and B. S. Bari, "Non-invasive blood glucose concentration level estimation accuracy using ultra-wide band and artificial intelligence," *SN Applied Sciences*, Springer Nature Journal, Switzerland, vol. 20, article # 278, pages 9, 2020, doi: <https://doi.org/10.1007/s42452-019-1884-3>.
- [117] Q. Fang, and D. A. Boas, "Monte Carlo simulation of photon migration in 3D turbid media accelerated by graphics processing units," *Optics Express*, OSA Publishing, vol. 17, no. 22, pp. 20178-20190, 2009, doi: <https://doi.org/10.1364/OE.17.020178>.
- [118] S. Yan, and Q. Fang, "Hybrid mesh and voxel based Monte Carlo algorithm for accurate and efficient photon transport modeling in complex bio-tissues," *Biomedical Optics Express*, OSA Publishing, vol. 11, no. 11, 2020, doi: 10.1364/boe.409468.
- [119] M. Althobaiti and I. Al-Naib, "Optimization of Dual-Channel Near-Infrared Non-Invasive Glucose Level Measurement Sensors Based on Monte-Carlo Simulations," *IEEE Photonics Journal*, vol. 13, no. 3, pp. 1-9, June 2021, article no. 3700109, doi: 10.1109/JPHOT.2021.3079408.
- [120] B. Kapilevich and B. Litvak, "Optimized Microwave Sensor for Online Concentration Measurements of Binary Liquid Mixtures," *IEEE Sensors Journal*, vol. 11, no. 10, pp. 2611-2616, October 2011, doi: 10.1109/JSEN.2011.2149517.
- [121] B. Camli, E. Kusakci, B. Lafci, S. Salman, H. Torun and A. D. Yalcinkaya, "Cost-Effective, Microstrip Antenna Driven Ring Resonator Microwave Biosensor for Biospecific Detection of Glucose," *IEEE Journal of Selected Topics in Quantum Electronics*, vol. 23, no. 2, pp. 404-409, March-April 2017, Art no. 6900706, doi: 10.1109/JSTQE.2017.2659226.
- [122] M. Koutsoupidou, H. Cano-Garcia, R. L. Pricci, S. C. Saha, G. Palikaras, E. Kallos and P. Kosmas, "Study and Suppression of Multipath Signals in a Non-Invasive Millimeter Wave Transmission Glucose Sensing System," *IEEE Journal of Electromagnetics, RF and Microwaves in Medicine and Biology*, vol. 4, no. 3, pp. 187-193, September 2020, doi: 10.1109/JERM.2019.2938876.
- [123] H. Choi J. Naylor, S. Luzio, J. Beutler, J. Birchall, C. Martin, and A. Porch, "Design and In Vitro Interference Test of Microwave Noninvasive Blood Glucose Monitoring Sensor," *IEEE Transactions on Microwave Theory and Techniques*, vol. 63, no. 10, pp. 3016-3025, October 2015, doi: 10.1109/TMTT.2015.2472019.
- [124] L. O. Bagio, "Finite Element Modeling of Electrochemical Biosensors," MSc in EE Thesis, December 2018, California State University, Northridge, USA, URL: <http://hdl.handle.net/10211.3/207848>.
- [125] J. Vrba, J. Karch, and D. Vrba, "Phantoms for Development of Microwave Sensors for Noninvasive Blood Glucose Monitoring," *International Journal of Antennas and Propagation*, Hindawi Publishing Corporation, vol. 2015, article ID. 570870, 5 pages, doi: <http://dx.doi.org/10.1155/2015/570870>.
- [126] J. Karch, "Dielectric-properties measurements of glucose solutions and design of suitable measurement probe for noninvasive monitoring of blood glucose levels," MS Thesis, Faculty of Biomedical Engineering, Czech Technical University in Prague, Prague, Czech Republic, 2014.
- [127] J. Venkataraman and B. Freer, "Feasibility of non-invasive blood glucose monitoring: In-vitro measurements and phantom models," *IEEE International Symposium on Antennas and Propagation (APSURSI)*, WA, USA, 2011, pp. 603-606, doi: 10.1109/APS.2011.5996782.
- [128] A. Kumar, C. Wang, F.-Y. Meng, Z.-L. Zhou, M. Zhao, G.-F. Yan, E.-S. Kim, and N.-Y. Kim, "High-Sensitivity, Quantified, Linear and Mediator-Free Resonator-Based Microwave Biosensor for Glucose Detection," *Sensors*, vol. 20, article no. 4024, July 2020, 17 pages, doi: 10.3390/s20144024.
- [129] M. S. Wróbel, "Non-invasive blood glucose monitoring with Raman spectroscopy: prospects for device miniaturization," 39th International Conference Microelectronics and Packaging (IMAPS), IOP Conference Series: Materials Science and Engineering, vol. 104, 2015, Poland, article no. 012036, doi:10.1088/1757-899X/104/1/012036.
- [130] S. P. Singh, S. Mukherjee, L. H. Galindo, P. T. C. So, R. R. Dasari, U. Z. Khan, R. Kannan, A. Upendran, and J. W. Kang, "Evaluation of accuracy dependence of Raman spectroscopic models on the ratio of calibration and validation points for non-invasive glucose sensing," *Analytical and Bioanalytical Chemistry*, vol. 410, no. 4, July 2018, pp. 6469-6475, doi: <https://doi.org/10.1007/s00216-018-1244-y>.
- [131] J. Kottmann, J. M. Rey, and M. W. Sigrist, "Mid-Infrared Photoacoustic Detection of Glucose in Human Skin: Towards Non-Invasive Diagnostics," *Sensors*, vol. 16, article no: 1663, 2016.
- [132] C. Jang, J.-K. Park, H.-J. Lee, G.-H. Yun, and J.-G. Yook, "Non-Invasive Fluidic Glucose Detection Based on Dual Microwave Complementary Split Ring Resonators with a Switching Circuit for Environmental Effect Elimination," *IEEE Sensors Journal*, vol. 20, 2020, pp. 8520-8527.
- [133] S. A. Siddiqui, Y. Zhang, J. Lloret, H. Song, and Z. Obradovic, "Pain-Free Blood Glucose Monitoring Using Wearable Sensors: Recent Advancements and Future Prospects," *IEEE Reviews in Biomedical Engineering*, vol. 11, 2018, pp. 21-35.
- [134] F. Tang, X. Wang, D. Wang, and J. Li, "Non-Invasive Glucose Measurement by Use of Metabolic Heat Conformation Method," *Sensors Journal*, vol. 8, no. 5, 2008, pp. 3335-3344, doi: <https://doi.org/10.3390/s8053335>.
- [135] O. K. Cho, Y. O. Kim, H. Mitsumaki, and K. Kuwa "Noninvasive measurement of glucose by metabolic heat conformation method," *Clinical Chemistry*, vol. 50, no. 10, October 2004, pp. 1894-1898, doi: 10.1373/clinchem.2004.036954. Epub 2004, Aug 12. PMID: 15308597.
- [136] T. Danne, R. Nimri, T. Battelino, R. M. Bergenstal, K. L. Close, J. H. DeVries, S. Garg, L. Heinemann, I. Hirsch, S. A. Amiel, R. Beck, E. Bosi et al., "International Consensus on Use of Continuous Glucose Monitoring," *Diabetes Care*, vol. 40, no. 12, 2017, pp. 1631-1640, doi: <https://doi.org/10.2337/dc17-1600>.
- [137] F. Reiterer, P. Polteraue, M. Schoemaker, G. S.-Redecker, G. Freckmann, L. Heinemann, L. delRe, "Significance and Reliability of MARD for the Accuracy of CGM Systems," *Journal of Diabetes Science and Technology*, vol. 11, 2017, pp. 59-67.
- [138] T. S. Bailey, "Clinical Implications of Accuracy Measurements of Continuous Glucose Sensors," *Diabetes Technology and Therapeutics*, vol. 19, no. S2, May 2017, pp. S51-S54, doi:10.1089/dia.2017.0050.
- [139] R. R. Chai and T. Draxler, "Root Mean Square Error (RMSE) or Mean Absolute Error (MAE)? - Arguments Against Avoiding RMSE in the Literature," *Geosci. Model Dev.*, vol. 7, 2014, pp. 1247-1250, <https://doi.org/10.5194/gmd-7-1247-2014>.
- [140] R. Pamungkas, A. Putrada, and M. Abdurroham, "Performance Improvement of Non Invasive Blood Glucose Measuring System With Near Infra-Red Using Artificial Neural Networks," *Kinetik: Game Technology, Information System, Computer Network, Computing, Electronics, and Control*, ISSN: 2503-2267, vol. 4, no. 4, November 2019, pp. 315-324, doi: <http://dx.doi.org/10.22219/kinetik.v4i4.844>.
- [141] S. A. Boren and W. L. Clarke, "Analytical and Clinical Performance of Blood Glucose Monitors," *Journal of Diabetes Science and Technology*, vol. 4, 2010, pp. 84-97.
- [142] D. C. Klonoff, C. Lias, R. Vigersky, W. Clarke, J. L. Parkes, D. B. Sacks, M. S. Kirkman, B. Kovatchev, "The Surveillance Error Grid," *Journal of Diabetes Science and Technology*, vol. 8, 2014, pp. 658-672.
- [143] D. C. Klonoff, "The Need for Clinical Accuracy Guidelines for Blood Glucose Monitors," *Journal of Diabetes Science and Technology*, vol. 6, 2012, pp.1-4.
- [144] W. L. Clarke, D. Cox, L. A. G.-Frederick, W. Carter, and S. L. Pohl, "Evaluating clinical accuracy of systems for self-monitoring of blood glucose," *Diabetes Care*, vol. 10, 1987, pp. 622-628.
- [145] Diabetes Care uses Clarke Error Grid Analysis (EGA) Analysis: http://care.diabetesjournals.org/cgi/content/abstract/10/5/622?ijkey=959ce0073ff9f91dfd78630b4259267d96a9db0f&keytype=tf_ipsecsha, accessed on 7 August 2021.
- [146] J. L. Parkes, S. L. Slatin, S. Pardo, and B. H. Ginsberg, "A new consensus error grid to evaluate the clinical significance of inaccuracies in the measurement of blood glucose," *Diabetes Care*, vol. 23, no. 8, August 2000, pp. 1143-1148, <https://doi.org/10.2337/diacare.23.8.1143>.
- [147] ISO Focus, The Magazine of the International Organization for Standardization, vol. 6, no. 2, February 2009, ISSN 1729-8709, p. 32.
- [148] International Organization for Standardization (ISO). Available online: <https://www.iso.org>, accessed on 28 August 2021.
- [149] N. Jendrike, A. Baumstark, U. Kamecke, C. Haug, and G. Freckmann, "ISO 15197: 2013 Evaluation of a Blood Glucose Monitoring System's Measurement Accuracy," *Journal of Diabetes Science and Technology*, vol. 11, no. 6, November 2017, pp. 1275-1276, PMID: PMC5951056, PMID: 28849677, doi: <https://doi.org/10.1177/1932296817727550>.
- [150] A. Baumstark, C. Schmid, S. Pleus, D. Rittmeyer, C. Haug, and G. Freckmann, "Accuracy Assessment of an Advanced Blood Glucose Monitoring System for Self-Testing With Three Reagent System Lots Following ISO 15197:2013," *Journal of Diabetes Science and Technology*, vol. 8, no. 6, August 7, 2014; pp. 1241-1242. doi:10.1177/1932296814546529.
- [151] S. Pleus, A. Baumstark, N. Jendrike, J. Mende, M. Link, E. Zschornack, C. Haug, and G. Freckmann, "System accuracy evaluation of 18 CE-

- marked current-generation blood glucose monitoring systems based on EN ISO 15197:2015,” *BMJ Open Diabetes Research and Care* vol. 8, e001067, 2020; doi: 10.1136/bmjdr-2019-001067.
- [152] W. V. Gonzales, A. T. Mobashsher, and A. Abbosh, “The Progress of Glucose Monitoring—A Review of Invasive to Minimally and Non-Invasive Techniques, Devices and Sensors,” *Sensors*, vol. 19, 2019, article no. 800, p. 9, doi: 10.3390/s19040800.
- [153] International Organization for Standardization (ISO). ISO 15197:2013. In *Vitro Diagnostic Test Systems—Requirements for Blood-Glucose Monitoring Systems for Self-Testing in Managing Diabetes Mellitus*; International Organization for Standardization (ISO): Geneva, Switzerland, 2013.
- [154] G. Freckmann, A. Baumstark, N. Jendrike, D. Rittmeyer, S. Pleus, and C. Haug, “Accuracy Evaluation of Four Blood Glucose Monitoring Systems in the Hands of Intended Users and Trained Personnel Based on ISO 15197 Requirements,” *Diabetes Technology and Therapeutics*, vol. 19, 2017, pp. 246-254.
- [155] International Organization for Standardization (ISO). International Organization for Standardization (ISO). *In vitro diagnostic test systems—Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus (ISO 15197:2013)*. In EN ISO 15197:2015; International Organization for Standardization (ISO): Geneva, Switzerland, 2015.
- [156] G. Freckmann, C. Schmid, A. Baumstark, M. Rutschmann, C. Haug, and L. Heinemann, “Analytical Performance Requirements for Systems for Self-Monitoring of Blood Glucose with Focus on System Accuracy: Relevant Differences among ISO 15197:2003, ISO 15197:2013, and Current FDA Recommendations,” *Journal of Diabetes Science and Technology*, vol. 9, 2015, pp. 885-894.
- [157] US Food and Drug Administration (FDA). *Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use*; US Food and Drug Administration (FDA): Silver Spring, MD, USA, 2016.
- [158] US Food and Drug Administration (FDA). *Self-Monitoring Blood Glucose Test Systems for over-the-Counter Use*; US Food and Drug Administration (FDA): Silver Spring, MD, USA, 2016.
- [159] European Commission. *In vitro Diagnostic Medical Devices*. Online: <http://ec.europa.eu/growth/single-market/european-standards/harmonised-standards/iv-diagnostic-medical-devices/#Note%202.1>, accessed on 12 August 2021.
- [160] Government of Canada. *New Requirements for Medical Device License Applications for Lancing Devices and Blood Glucose Monitoring Systems*. Online: <https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/activities/announcements/notice-new-requirements-medical-device-licence-applications-lancing-devices-blood-glucose-monitoring-systems.html>, accessed on 12 August 2021.
- [161] Agência Nacional de Vigilância Sanitária (ANVISA). *Instrução Normativa Nº 24; Agência Nacional de Vigilância Sanitária (ANVISA)*: Brasília, Brazil, 2018.
- [162] China Food & Drug Administration (CFDA). *Glucometer Registration Technical Review Guidelines; Chemical Inspection and Regulation Service (CIRS)*: Beijing, China, 2016.
- [163] Pharmaceuticals and Medical Devices Agency (PMDA). *Handling of Self-Testing Blood Glucose Meters*. Online: http://www.std.pmda.go.jp/stdDB/Data/MDStd/CerStd/Notif/K1100009_01_2016_en.pdf, accessed on 2 August 2021.
- [164] Pharmaceuticals and Medical Devices Agency (PMDA). *List of Certification Standards; Pharmaceuticals and Medical Devices Agency (PMDA)*: Tokyo, Japan, 2018.
- [165] Department of Therapeutic Goods Administration (TGA). *Australian Regulatory Guidelines for Medical Devices (ARGMD)*. Online: <https://www.tga.gov.au/publication/australian-regulatoryguidelines-medical-devices-argmd>, accessed on 5 August 2021.
- [166] Standards Australia. ISO 15197:2013. Online: <https://www.standards.org.au/standardscatalogue/international/iso-slash-tc--212/iso--15197-colon-2013>, accessed on 5 August 2021.
- [167] Department of Therapeutic Goods Administration (TGA). *Medical Devices Regulation: An Introduction*. Online: <http://www.tga.gov.au/sme-assist/medical-devices-regulation-introduction>, accessed on 5 August 2021.
- [168] I. Harman-Boehm, A. Gal, A. M. Raykhman, E. Naidis, and Y. Mayzel “Noninvasive glucose monitoring: increasing accuracy by combination of multi-technology and multi-sensors,” *Journal of Diabetes Science and Technology*, vol. 4, no. 3, May 2010; pp. 583-595, doi: <https://doi.org/10.1177/193229681000400312>.
- [169] Continuous Blood Glucose Monitoring via a Fiber Optic Sensor, <https://en.eyesense.com/>, accessed on 6 August 2021.
- [170] Invisible Eye Glucose Monitor Accurately Measures Sugar Levels, <https://www.labiotech.eu/more-news/noviosense-glucose-monitor-diabetes/>, accessed on 6 August 2021.
- [171] A. E. Kownacka, D. Vegelyte, M. Joesse, N. Anton, B. J. Toebes, J. Lauko, I. Buzzacchera, K. Lipinska, D. A. Wilson, N. Geelhoed-Duijvestijn, and C. J. Wilson, “Clinical Evidence for Use of a Noninvasive Biosensor for Tear Glucose as an Alternative to Painful Finger-Prick for Diabetes Management Utilizing a Biopolymer Coating,” *Bio macromolecules*, vol. 19, no. 11, 2018, pp. 4504-4511, ACS Publications, doi: 10.1021/acs.biomac.8b01429.
- [172] Glucose Measurement System Skips the Finger Stab, <https://healthtechinsider.com/2021/05/04/glucose-measurement-system-skips-the-finger-stab-video/>, accessed on 10 August 2021.
- [173] C8 Non-Invasive Optical Glucose Monitor System Cleared for Sale in Europe <https://www.medgadget.com/2012/10/c8-non-invasive-optical-glucose-monitor-system-cleared-for-sale-in-europe-video.html>, accessed on 10 August 2021.
- [174] Non-invasive continuous blood glucose monitoring. Online: <https://patents.google.com/patent/US5823966A/en>, accessed on 7 August 2021.
- [175] C. D. Malchoff, J. I. Landau, K. Shoukri, J. M. Buchert, “A Novel Noninvasive Blood Glucose Monitor,” *Diabetes Care*, vol. 25, no. 12, December 2002, pp. 2268-2275.
- [176] Glucose Monitor Uses LASER Sensor: Device could replace implants and frequent finger pricking for diabetics, report published in The International Society for Optics and Photonics (SPIE) on 01 October 2015. Online: <https://spie.org/news/spie-professional-magazine-archive/2015-october/pbw-glucose-monitor-laser-sensor?SSO=1>, accessed on 6 August 2021.
- [177] Measure blood sugar with light. <https://scienceinfo.net/measure-blood-sugar-with-light.html>, accessed on 7 August 2021.
- [178] Hitachi Developing Non-Invasive Blood Sugar Monitoring Device-Proprietary Technologies would take the Pain and Hassle out of Measuring Blood Sugar Levels. Online: <https://www.hitachi.com/New/cnews/040223.html>, accessed on 7 August 2021.
- [179] Biosensors Inc. Online: <http://www.biosensors-tech.com/technology.php>, accessed on 7 August 2021.
- [180] R. Weiss, Y. Yegorchikov, A. Shusterman, and I. Raz, “Noninvasive Continuous Glucose Monitoring Using Photoacoustic Technology—Results from the First 62 Subjects,” *Diabetes Technology and Therapeutics*, vol. 9, no. 1, February 2007, doi: <https://doi.org/10.1089/dia.2006.0059>.
- [181] Glucon: Blood Sugar Magic. Online: https://www.medgadget.com/2005/06/glucon_blood_su.html, accessed on 7 August 2021.
- [182] World's first blood sampling-free (non-invasive) blood glucose sensor using advanced laser technology. Light Touch Technology (LTT), <http://www.light-tt.co.jp/product?lang=en>, accessed on 7 August 2021.
- [183] ESER G2 Mobile-Noninvasive Glucose Monitor. Online: <http://www.eserdigital.com/productform/42-en.html>, accessed on 7 August 2021.
- [184] MediWise. GlucoWise. Available online: <http://www.gluco-wise.com/>, accessed on 6 August 2021.
- [185] S. Saha, H. Cano-Garcia, I. Sotiriou, O. Lipscombe, I. Gouzouasis, M. Koutoupidou, G. Palikaras, R. Mackenzie, T. Reeve, P. Kosmas, and E. Kallos, “A Glucose Sensing System Based on Transmission Measurements at Millimeter Waves using Micro strip Patch Antennas,” *Scientific Reports*, vol. 7, no. 1, July 2017, Article 6855, p. 1-11, doi: 10.1038/s41598-017-06926-1.
- [186] A. DeHennis, S. Tankiewicz, T. Whitehurst, Analyte Sensor. US Patent US 9,901,293 B2, 24 February 2015.
- [187] R. Z. Jafri, C. A. Balliro, F. El-Khatib, M. Maheno, M. A. Hillard, A. J. Donovan, R. Selagamsetty, H. U. I. Zheng, E. Damiano, S. J. Russell, “A Three-Way Accuracy Comparison of the Dexcom G5, Abbott Freestyle Libre Pro, and Senseonics Eversense CGM Devices in an Outpatient Study of Subjects with Type 1 Diabetes,” *Diabetes*, vol. 67, July 2018, doi: <https://doi.org/10.2337/db18-14-OR>.
- [188] Senseonics. Eversense User Guide. Online: <https://www.ascensidiabetes.com/eversense/eversense-cgm-system/>, accessed on 7 August 2021.

- [189] Y. (J.) Segman, "Device and Method for Noninvasive Glucose Assessment," *Journal of Diabetes Science and Technology*, vol. 12, no. 6, 2018, pp. 1159-1168, doi: 10.1177/1932296818763457.
- [190] Measure blood sugar with light. <https://scienceinfo.net/measure-blood-sugar-with-light.html>, accessed on 7 August 2021.
- [191] Tech4Life Enterprises, Non-Invasive Glucometer, <https://tech4lifeenterprises.com/non-invasive-glucometer/>, accessed on 18 August 2021.
- [192] World Global Network (WGN), Helo Extense. <https://website.worldgn.com/heloextense/>, accessed on 15 August 2021.
- [193] Nemaura Medical, SugarBEAT® Complete FDA Clinic Data file, "A Prospective Single Centre Evaluation of the Accuracy and safety of the sugarBEAT® Non-invasive Continuous Glucose Monitor (CGM) System," 18 December 2018, European Clinical Program, <https://nemauramedical.com/publications/>, accessed on 5 August 2021.
- [194] E. Hadar, R. Chen, Y. Toledano, K. Tenenbaum-Gavish, Y. Atzmon, and M. Hod, "Noninvasive, continuous, real-time glucose measurements compared to reference laboratory venous plasma glucose values," *The Journal of Maternal-Fetal and Neonatal Medicine*, vol. 32, no. 20, April 2018, pp. 3393-3400, doi: <https://doi.org/10.1080/14767058.2018.1463987>.
- [195] <https://nfb.org/sites/default/files/images/nfb/publications/vod/vod212/vodspr0601.htm>, accessed on 7 August 2021.



Muhibul Haque Bhuyan (MIEEE2005–)

became a Member (M) of the World Academy of Science, Engineering and Technology in 2005, born in Dhaka, Bangladesh on 25 July 1972. He did his BSc, MSc, and PhD degrees in Electrical and Electronic Engineering (EEE) from Bangladesh University of Engineering and Technology (BUET), Dhaka, Bangladesh in 1998, 2002, and 2011 respectively. Currently, he is working as a Professor of the Department of Electrical and Electronic Engineering of Southeast University, Dhaka, Bangladesh. He led this department as the Departmental Chairman from 1st March 2016 to 10th March 2021. Previously, he worked at the Green University of Bangladesh, Dhaka as a Professor and Chairman of the EEE Department; Daffodil International University, Dhaka, Bangladesh as an Assistant Professor and Head of ETE Department; Presidency University, Dhaka, Bangladesh as an Assistant Professor and American International University Bangladesh (AIUB), Dhaka as a Faculty Member since June 1999. He also worked as a Researcher in the Center of Excellence Program of Hiroshima University, Japan from July 2003 to March 2004. He has served as an Adjunct Faculty at AUST, IIUC, EWU, DIU, PU, etc. So far, he has published over 60 research papers in national and international journals and presented over 50 research works at national and international conferences. His research interests include MOS device modeling, biomedical engineering, control system design, online practices of teaching and learning, outcome-based engineering education, assessment, and evaluation. He is a program evaluator of the Board of Accreditation of Engineering and Technical Education (BAETE), Dhaka, Bangladesh under IEB.

Prof. Bhuyan is a Member of IEEE, USA, Executive Member of Bangladesh Electronics and Informatics Society (BEIS), and Fellow of the Institution of Engineers Bangladesh (IEB). He is a regular reviewer and technical/editorial/organizing committee member of several national and international journals and conferences. He was the Organizing Chair of the IEEE 22nd International Conference on Computer and Information Technology (ICCIT) held at Southeast University, Dhaka, Bangladesh during 18-20 December 2019. He is the recipient of the Bangladesh Education Leadership Awards (Best Professor in Electrical Engineering) in 2017 from the South Asian Partnership Awards, Mumbai, India.